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Summary 
 
Clinical imaging modalities have reached a prominent role in medical 
diagnosis and patient management in the last decades. Different image 
methodologies as Positron Emission Tomography, Single Photon Emission 
Tomography, X Rays or Magnetic Resonance Imaging are in continuous 
evolution to satisfy the increasing demands of current medical diagnosis. 
Progress in these methodologies has been favored by the parallel 
development of increasingly powerful contrast agents. These are 
molecules that enhance the intrinsic contrast of the images in the regions 
where they accumulate, improving both sensitivity and specificity in the 
diagnosis. The contrast agent field is also evolving to improve the 
performance of these molecules using the novel approaches that modern 
Nanotechnology offers. In this thesis, I will describe novel generations of 
advanced contrast agents with multimodal imaging applications based in 
nanotechnology developments. Chapter 1 introduces the different 
imaging modalities used in clinic and the first generation of contrast 
agents used. Chapter 2 presents a systematic study and evaluation of a 
novel nanoparticulate contrast agent useful in Magnetic Resonance 
Imaging measurements of tumor perfusion and immune response. 
Chapter 3 describes the development of a new theragnostic composition 
based in liposomes containing both, a therapeutic molecule and an 
imaging biomarker. The efficacy of this new formulation is validated 
using different animal models of colonic inflammation and cancer and a 
variety of imaging techniques. Finally, in Chapter 4 I develop and 
implement a new anisotropic contrast agent for Magnetic Resonance 
Imaging based in the unusual magnetic properties of Carbon Nanotubes. 
I characterize their magnetic properties and their potential use as 
advanced anisotropic contrast agents. In summary, in this work I 
propose, develop and evaluate a second generation of nanoparticulate 
contrast agents and their potential applications in advanced multimodal 
imaging. 
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Resumen 
Las distintas modalidades de Imagen Clínica han alcanzado una gran 
importancia en el diagnóstico médico y en el manejo clínico de los 
pacientes durante las últimas décadas. Las diferentes metodologías de 
imagen médica como Tomografía por Emisión de Positrones, Tomografía 
por Emisión de Fotón Único, Rayos X o Imagen por Resonancia Magnética 
han estado en continuo desarrollo para satisfacer la creciente demanda 
de diagnóstico médico. El progreso de estas metodologías se ha visto 
favorecido por el desarrollo en paralelo de agentes de contraste más 
potentes y eficaces. Estas moléculas aumentan el contraste intrínseco de 
las imágenes en las regiones donde se acumulan aumentando tanto la 
sensibilidad como la especificidad en el diagnóstico. El campo de los 
agentes de contraste está actualmente en continua evolución 
aprovechando en las nuevas oportunidades que ofrece la 
Nanotecnología. En esta tesis, describiré nuevos agentes de contraste 
con aplicaciones en imagen multimodal basados en recientes desarrollos 
nanotecnológicos. El Capítulo 1 presenta las diferentes modalidades de 
imagen usadas en clínica y la primera generación de agentes de 
contraste. El Capítulo 2 describe el estudio sistemático y la evaluación de 
un nuevo agente de contraste nanoparticulado útil en medidas de 
perfusión tumoral y respuesta inmunológica mediante Imagen por 
Resonancia Magnética. El Capítulo 3 presenta el desarrollo de una nueva 
composición teragnóstica basada en liposomas que contienen tanto una 
molécula terapéutica como un biomarcador para imagen médica. La 
eficacia de esta nueva formulación se comprueba mediante una variedad 
de técnicas de imagen y con diferentes modelos animales de inflamación 
y cáncer. Finalmente, en el Capítulo 4, describe el desarrollo y 
caracterización de un nuevo agente de contraste anisotrópico para 
Imagen por Resonancia Magnética que aprovecha las extraordinarias 
propiedades magnéticas de los Nanotubos de Carbono. En el capítulo, se 
investigan sus propiedades magnéticas y su potencial utilización como 
agentes de contraste avanzados  de naturaleza anisotrópica. En resumen, 
en este trabajo se desarrolla, caracteriza y evalúa una nueva generación 
de agentes de contraste nanoparticulados y sus aplicaciones en técnicas 
de imagen multimodal.  
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Chapter 1 
Introduction 
 
Chapter 1 provides an introduction to the 
different multimodal bioimaging methods 
presently used as diagnostic tools in the clinic 
and the contrast agents currently available to 
enhance their image quality and information. 
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1.1. Multimodal Molecular Imaging 
Biomedical images originate from the interaction between an 
electromagnetic radiation and the biological specimen. The 
electromagnetic spectrum (Figure 1.1) spans from the shortest 
wavelengths and highest energies associated to the cosmic rays to the 
longest wavelengths and lowest energies associated to the heating 
radiation. The γ-radiation, X-rays, ultraviolet, visible and infrared lights, 
micro- or radiofrequency waves and also heat, lay in between these two 
extremes.
 
Figure 1.1. The electromagnetic spectrum expressed as energy (top) or 
associated wavelength (bottom). The middle panel shows some of the initial 
images obtained from each modality including radiofrequency (MRI) [1], infrared 
[2], X-Rays [3], and γ-rays (PET) [4]. 
Nuclear medicine approaches involve the use of highly penetrating γ- and 
x-ray radiations, generating high sensitivity (10-12 M) images with limited 
resolution (mm). Optical images may become very sensitive (10-15M), as 
in microscopy, but their penetration capacity within the biological 
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specimen is limited in vivo (mm) and only, very thin objects or highly 
superficial processes, can be imaged. Finally, radiofrequency imaging 
provides excellent penetration capacity and resolution (µm), at the 
expense of very limited sensitivity (10-3M). Taken together, these 
considerations suggest that there is no single optimal imaging modality, 
all of them presenting advantages and limitations. This provides a sound 
basis to combine the different imaging modalities in a hybrid manner to 
obtain a single multimodal image including the information derived from 
the different modalities, thus overcoming the specific limitations of each 
modality with the advantages of the others [5].  
The physical interaction between the radiation and the specimen 
involves most of the times, its transmittance though the biological 
medium and the detection of the transmitted radiation across the object 
with suitable detectors [6]. This is the case of optical imaging and nuclear 
imaging. The image generated follows then the Lambert-Beer Law 
 Eq. 1.1 
where  is the intensity of the image detected,  the intensity of the 
radiation source before the interaction, is the extinction coefficient 
revealing the density of the specimen towards the transmitted radiation 
in a unit of length and d the distance travelled by the radiation through 
the object. In the case of nuclear imaging, the source of radiation is 
inside the specimen and decays rapidly with time because of the 
radioactive decay law, so corrections need to be done to account for this 
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circumstance, particularly in the case of positron emitters with very short 
half-lives.  
In general, a planar image is obtained after detecting the transmitted 
radiation either with a digital camera in the case of optical imaging, or 
through a coronal array of highly efficient scintillation detectors in 
nuclear imaging [6, 7]. The reconstruction process, normally used in X-
rays and nuclear medicine approaches, was first proposed by Godfrey 
Hounsfield and plays a fundamental role in nuclear imaging [8]. Since 
then a variety of reconstruction algorithms have been proposed with 
increasing resolution and computing time efficiency [9]. 
The discovery of Magnetic Resonance Imaging disclosed a completely 
new imaging strategy, not based on the transmittance phenomenon [1]. 
Rather, it took advantage of new physical interaction, based in the 
magnetic properties of biological nuclei in the sample and how they 
interact with static and dynamic external magnetic fields. The method 
used non-ionizing radiation and presented improved resolution when 
compared to nuclear medicine and in vivo optical imaging approaches, at 
the expense of a more limited sensitivity. More details on this method 
are provided in the next sections. 
Despite the intrinsic image contrast determined by the physical 
properties of the tissues, the use of exogenous contrast enhancing 
molecules has been generalized in all imaging modalities [10-14]. These 
molecules are designed to enhance selectively and sensitively the 
intensity of the images in regions of tissue presenting particular 
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physiological, cellular or molecular properties, favoring enormously the 
recent development of the molecular and cellular imaging field [15].  
The initial contrast agents were chemicals with subnanometric 
dimensions active in the different regions of the electromagnetic 
spectrum. Briefly, periodinated benzenes, Gadolinium chelates and 99mTc 
derivatives were among the first contrast agents used in X-ray, MRI, and 
nuclear medicine, respectively [11, 16, 17]. More recently, 
nanostructured materials have shown improved resolution and 
sensitivity properties with respect to the classical chemicals, as well as 
capacity to operate as multifunctional diagnostic and therapeutic 
(theragnostic) agents, thus opening a new horizon for the applications of 
nanotechnology in biomedical imaging [18, 19]. 
In this thesis I will describe new generations of nanostructured contrast 
agents with improved performance in Magnetic Resonance Imaging and 
the potential use as theragnostic drugs. First, I will describe the 
fundamentals of Magnetic Resonance and Magnetic Resonance Imaging. 
Second, I will present a new superparamagnetic nanoparticle with 
improved pharmacokinetic properties, able to generate high quality 
images of tumoral perfusion. Third, I will investigate the encapsulation in 
liposomes of superparamagnetic nanoparticles, rhodamine-100 
(rhodamine-100 chloride) and / or omega-3 polyunsaturated fatty acid 
ethyl ester to evaluate their efficacy as a novel anti-inflammatory 
theragnostic agent. Finally, I will implement the use of single wall and 
multiwall carbon nanotubes, as molecular anisotropy probes able to 
encode directionality in MRI images.  
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1.1.1. Magnetic Resonance Imaging 
The Magnetic Resonance Phenomenon 
MRI techniques are based on the outstanding physical properties of the 
Nuclear Magnetic Resonance (NMR) phenomenon, as described by Felix 
Bloch [20] and Edward Mills Purcell [21] in 1946. This phenomenon is 
based on the fact that nuclei inside a magnetic field absorb 
electromagnetic radiation at a specific frequency, emitting the same 
radiation after the relaxation of the nuclei occurs [22, 23]. The frequency 
of this radiation depends on the magnetic field applied to the nuclei 
being excited. Not all nuclei present this phenomenon. It is necessary for 
the nuclei to have a non-zero spin value (an intrinsic quantum property) 
which leads in a non-zero magnetic moment ( ) with a gyromagnetic 
ratio ( ). Thus, a nucleus like 1H presents NMR absorption, while 18O does 
not present it. Due to the quantum nature of the spin ( ), the magnetic 
moment presents only certain allowed values, depending on the 
magnetic quantum number m. So the z component of the magnetic 
moment of a nucleus is given by: 
 Eq. 1.2 
where  is the Planck constant divided by 2π (the z component refers to 
the magnetization vector S along the direction of the static magnetic field 
B0). If we introduce the nucleus in a magnetic field, the next expression 
for the energy of this system applies: 
 Eq. 1.3 
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For a two spin state ( ) nucleus like the 1H, the difference in 
energy between the stationary state and the excited state is given by: 
 Eq. 1.4 
And, since the difference in energy between two nuclear states is given 
by  
 Eq. 1.5 
the frequency of the radiation needed to excite the nuclei and induce a 
transition (as well as the frequency of the radiation emitted in the 
corresponding relaxation process) is given by 
 Eq. 1.6 
Each nucleus presents a characteristic gyromagnetic ratio so the 
resonance frequency is specific for every nucleus even if placed in the 
same magnetic field. This characteristic resonance frequency is known as 
the Larmor frequency. 
Once the nuclei have been excited, the magnetization acquired is 
eventually lost to the surroundings mainly through two magnetic 
relaxation processes, longitudinal or spin-lattice (T1) and transversal or 
spin-spin (T2) relaxation. The T1 process (Figure 1.2) determines the 
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relaxation occurring in the z-axis, while the T2 process (Figure 1.3) 
determines the magnetic relaxation in the x-y plane.  
 
Figure 1.2. Scheme of T1 relaxation. When the sample is excited with an RF 
pulse (left), some of the spins change their orientation and energy, resulting in a 
net decrease of the longitudinal magnetization component (center). When the 
pulse is turned off, the magnetization recovers to its original equilibrium value 
(right) with a time constant T1. 
The relaxation processes implies the loss of the magnetization acquired 
during the excitation process to the surroundings (lattice, in the T1 
process) or to other nuclei (spin-spin, T2). 
 
Figure 1.3. Scheme of T2 relaxation. When the sample is excited with an RF 
pulse (left), the excited spins precess in phase, resulting in the appearance of net 
coherent transversal magnetization (center). When the pulse is turned off, the 
transversal magnetization loses coherence progressively and returns to its zero 
equilibrium value (right). 
Field inhomogeneities may result in additional dephasing of the spins in 
the x-y plane in a process known as T2*. In the presence of field 
inhomogeneities, as it happens in biological tissues, T2* is always smaller 
than T2. 
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Magnetic Resonance Imaging 
Magnetic resonance imaging obtains images from biological objects by 
encoding the magnetization of every pixel in the three spatial 
coordinates x, y and z. This is done through the application of field 
gradients that encode the z and x coordinates as frequency dependent 
and the y coordinate as a phase dependence [1]. Briefly, the three 
dimensional localization of every pixel is encoded using either field or 
phase gradients 
 Eq. 1.7 
 Eq. 1.8 
One of the most commonly used sequences is the spin-echo sequence 
(Figure 1.4). The sequence consist of two sequential radiofrequency 
pulses, the first one  is used to excite the sample while the second one is 
used to rephase the protons in the x-y plane (these pulses are separated 
by a time known as echo time TE/2, where TE is the time between the 
first pulse and the maximal echo signal). The spin-echo sequence is 
repeated for every value of the phase encoding gradient with a delay 
time known as repetition time, TR, used to recover the longitudinal 
magnetization before the next pulse train. 
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Figure 1.4. Spin-echo sequence. The top trace corresponds to the 
radiofrequency pulse train (π/2, π, echo) and the lower ones to the slice 
selection gradient (next to top), the variable phase encoding gradient (middle) 
and the readout gradient of the echo (bottom trace). TE is the time between the 
/2 pulse and the echo and TR is the time between two successive /2 pulses. 
The different echo signals S obtained in the time domain for every value 
of the phase gradient (k space), are digitized and transformed 
bidimensionally into a frequency map (the image) using the Fourier 
Transform theorem: 
 Eq. 1.9 
where  is the signal intensity in the frequency domain and the 
signal intensity (microvolts) in the time domain. 
The signal intensity  obtained in every pixel after the Fourier 
Transformation follows the equation 
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 Eq. 1.10 
where  is the spin density, TE the echo time, TR the repetition time , T1 
the longitudinal relaxation time and T2 the transversal relaxation time 
[22]. It is possible to weight the signal intensity of the pixel in T1, T2 or  
choosing the proper pulsing conditions. Using, very short TE (much 
shorter than T2) and TR values shorter than T1, the image is said to be 
dominated by the T1 relaxation terms, or “weighted in T1”. Using very 
long TRs (longer than T1) and TE values in the range of T2, the image 
obtained is said to be dominated by the T2 term, or “weighted in T2”. 
Finally, using very long TR values (much longer than T1) and very short TE 
values (much shorter than T2), the T1 and T2 influences are minimized and 
the image is said to be weighted in proton density ( ). 
1.1.2. Optical Imaging 
Optical Imaging is a technique that permits the measurement of light 
produced in vivo by fluorescence or bioluminescence mechanisms. It is a 
non-invasive procedure with low resolution but with high sensitivity [24, 
25]. 
This effect is based in the luminescence effect where some chemical 
compounds absorb radiation and produce then light of a well-known 
frequency. A usual chemical compound used in this technique is luminol 
which in presence of myeloperoxidase or iron complex as catalysts 
suffers a reaction generating chemiluminiscence [26, 27]. This effect is 
used in detecting inflammations (Figure 1.5). 
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Figure 1.5. Representative bioluminescence images obtained after the 
administration of luminol. Two mice subjected to sodium dextran sulfate 
(DSS) intoxication are investigated, one of them injected with luminol (left) and 
the other one without the optical agent (right). Note how inflammatory disease 
triggers myeloperoxidase expression in the neutrophils and the formation of 
bioluminescent derivative of luminol [24, 26]. 
The optical approach has been reinforced recently with the development 
of transgenic mice, carrying the luciferase promoter coupled to specific 
genes activated by inflammation (NFkappaB) or cancer (VEGF) [28, 29]. 
These mice, express the luciferase gene, every time the coupled gene is 
expressed, and consequently emit light spontaneously if luciferin is 
administered [30]. 
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1.1.3. Ionizing Radiation Imaging 
X-Rays 
The potential use of X-Rays as a tool in clinical imaging was first 
discovered by Wihelm Röntgen at the end of 19th century [3]. A high 
energetic electron beam emits radiation when the electrons are stopped. 
This is known as Bremsstrahlung radiation and has the enough energy to 
go through biological tissues being more attenuated by tissues containing 
large quantities of electron dense metals as calcium (as the bones or 
calcified lesions). So, if the tissue under study is accommodated between 
the electron beam source and a photograph film, images of bones or 
other electron dense tissues or implants can be obtained easily. 
Nowadays, X-Rays devices have evolved to obtain three-dimensional 
images or applied kinetically “on line” to measure transit times of the 
contrast agent in fluoroscopy studies [6, 31, 32]. 
Nuclear Radiation Imaging 
The development of new nuclear technologies and accelerators permit 
the manipulation of the energy levels of the nucleus to release radiations 
of high energy, known as gamma rays. Gamma rays are more energetic 
than X-Rays and go through biological tissue with low attenuation. Using 
cyclotrons it is possible to synthesize radiopharmaceuticals with high 
tissue specificity, emitting gamma photons only from the target tissue. 
SPECT (Single Photon Emission Computed Tomography) was the first 
device developed using this technology. The most common 
radiopharmaceutical used in SPECT 99mTc attached to a molecule 
(normally an antibody) with high specificity causing an accumulation of 
the radiopharmaceutical in a specific tissue (e.g., tumoral tissue). 99mTc 
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emits one photon of 140 keV for each disintegration (the half-life of 99mTc 
is around 6 hours) which is recollected and visualized with a gamma 
camera compound by scintillation detectors, many times based in 
sodium iodide crystals doped with thallium (NaI(Tl)). A 3D software 
reconstructs the distribution of the photons allowing the spatial 
localization of the radiopharmaceutical emitter. PET (Positron Emission 
Tomography) is another technique of Nuclear Radiation Imaging. In this 
case, the radiopharmaceutical used emits positrons which are 
annihilated with electrons emitting two 511 keV gamma photons, in 
opposite directions. These photons are collected in a detector ring 
containing specialized gamma cameras (based most frequently on 
lutetium oxyorthosilicate LSO crystals) which surrounds the object, 
animal or patient. Because the emission of two photons occurs in 
opposite directions, the reconstruction software works with the 
coincidence of the detection to locate the original site of positron 
emission. The PET technique presents, because of the higher energies 
involved, higher resolution than SPECT, but remains limited by the 
shorter half-life of the PET radiopharmaceuticals as compared to SPECT. 
Both techniques depict very high sensitivity, albeit low resolution, and 
are heavily used in cell tracking and tumor detection [33, 34] (Figure 1.6).  
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Figure 1.6. Representative PET image of a patient obtained after 18F-2-
deoxyglucose administration. Organs that take most contrast are brain, 
heart or bladder. It is possible to detect clearly a tumor in the liver (arrow) 
(taken from [33]). 
1.2. Contrast Agents 
Contrast agents are molecules active in the different frequencies of the 
electromagnetic spectrum able to enhance in the image particular 
regions of the imaged subject, in which they accumulate. Their 
accumulation is able to reveal specific receptor activations, different 
cellular or molecular processes, the extension of lesions and their 
pathophysiological properties or the response to therapies. The first 
generation of contrast agents involved small molecules with diameters 
much smaller than 1 nm [11]. 
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In the nuclear medicine field, a large variety of SPECT or PET tracers 
haven been proposed, with dominant applications in oncologic and 
neurodegenerative diseases. In general, PET or SPECT tracers contain two 
parts, a targeting moiety providing the selectivity to the imaged process 
and a radionuclide moiety, containing the radionuclide emitting gamma 
rays with 140 meV (SPECT) or 511 meV (PET) enabling the detection. The 
targeting moieties are vectorial reagents, including either small chelates 
or even peptides, proteins or antibodies with molecular specificity for the 
desired target [35]. The radionuclides involve mainly 99mTc, 68Ga, 111In or 
131I for SPECT or 18F, 11C, 15O for PET. 
A large variety of SPECT probes are commercially available to monitor 
most frequently perfusion [36], hypoxia [37], inflammation [38], thyroid 
function [39] or even cerebral activation [40]. Their main advantage is 
the possibility to use relatively low cost gamma cameras for detection, 
available in many hospitals and the relatively long half-lives of the SPECT 
emitters (in the hour range), while their main limitation is the reduced 
resolution of the SPECT method [5, 6]. This limitation is overcome in large 
part through the use of PET probes which offer increase spatial and 
temporal resolution, at the expense of the more expensive PET 
equipment and the reduced half-life (in the min range) of the positron 
emitters. 18F-2-deoxiglucose (FDG) is probably the most widely used PET 
tracer, despite its poor selectivity. FDG is taken up by virtually all tissues 
in an analogous manner to glucose, but it is not degraded by glycolysis, 
resulting in FDG accumulation in those regions with enhanced glucose 
transport. FDG reveals spectacularly the presence of tumors or 
metastases, regions of cerebral activation or even inflammatory lesions, 
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providing probably the most successful tracer in nuclear medicine. 
However, since glucose uptake is a universal process, the use of FDG is 
hampered by its lack of selectivity, making very difficult to discriminate 
tumoral from inflamed regions, resulting in a non-negligible number of 
false positives (up to 30% [41]) and requiring in many cases 
complementary examinations with other tracers or modalities.  
Contrast agents for MRI, involve mainly Gd(III) chelates, able to enhance 
water relaxation in those tissues where they accumulate [11]. Gd(III) is 
used because it has seven unpaired, slow relaxing electrons, and depicts 
the largest magnetic moment among the rare earth series. The ligands 
most frequently used are linear chelates derived from diethylendiamino 
pentaacetic acid (DTPA) or cyclic chelates derived from the tetra-aza-
macrocycles or cyclen derivatives (DOTA). In all these cases, the ligand 
provides eight binding sites anchoring the Gd(III), leaving free one the 
nine chelating sites of the metal, for water contact. The contact between 
water in the solution or tissue with the Gd(III), and the fast exchange of 
this water molecule with the bulk solution, reduces very significantly the 
relaxation times of the tissue, resulting in clearly enhanced image 
intensity in those regions containing the chelate [11]. The use of other 
lanthanides as Dy(III), may transform the same chelates in T2 enhancing 
probes, due to the inherent T2 relaxing properties of Dy(III) [42]. 
Currently there are no specific contrast agents to enhance T2*. In this 
thesis, I will provide an interesting alternative for this purpose. 
MRI includes additionally a large variety of molecules able to enhance 
image intensity using other mechanisms including mainly magnetization 
transfer methods [43]. These agents are known as diamagnetic Chemical 
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Exchange Saturation Transfer (CEST) or Paramagnetic Chemical Exchange 
Saturation Transfer (PARACEST) agents. These molecules can be 
customized to reveal important aspects of the lesions including 
properties of the microenvironment as pH [44], monovalent or divalent 
ion concentration [45] or temperature [46], among others. 
Superparamagnetic iron oxide nanoparticles have been implemented 
more recently to increase the relaxing capacity of the paramagnetic 
chelates [47-49]. These particles contain a magnetite core (Fe3O4) core, 
covered most frequently by a dextran or lipid coat. The particles are 
prepared by alkaline precipitation of mixtures of Fe3+ and Fe2+ in the 
presence of stabilizing agents as dextran or oleic acid. These depict 
enormous relaxivity values, as compared to the Gd(III) chelates, allowing 
for a significant increase in the sensivity for MRI detection. This is due to 
the fact that the cooperative alignment of the magnetic moments from 
the iron ions in the superparamagnetic nanoparticles, results in 
significantly larger magnetic moments than the additive alignment of the 
paramagnetic Gd(III) moments. Superparamagnetic behavior results 
mainly in T2 enhancement, in contrast with the paramagnetic T1 
enhancement, of the Gd(III) chelates. Little information exist of the T2* 
relaxing capacity of these particles [23]. In this thesis, I will describe a 
new iron-based nanoparticle coated with a polymer of acrylic acid, able 
to generate excellent T2* contrast. 
Finally, an ample collection of optical probes emitting fluorescence, 
luminescence or near infrared radiation, have been described [50-52]. 
These probes are limited by the reduced penetration in tissues of the 
optical wavelengths, but are well endowed to image small animals as 
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mice or cells, using the new generation of CCD (Charge Coupled Devices) 
cameras and optical scanners. However, the performance of these 
probes is supported by their excellent selectivity to respond to very 
specific molecular processes, as protease activation [51], angiogenesis 
[53] or inflammation [54]. 
The advent of Nanotechnology has provided a collection of new tools 
and formulations that may overcome the limitations of the first 
generation of contrast agents (Figure 1.7). Basically, the use of 
nanoparticles, decorated with vectorial molecules as antibodies or 
peptides may increase significantly the molecular selectivity of contrast 
agents, otherwise non selective, and the use of liposomal formulations 
may allow to combine probes for different imaging modalities in the 
same vehicle, or even add a therapeutic molecule. Moreover, these novel 
formulations are expected to decrease the dose of administered contrast 
required for successful imaging, since most of the non-selective contrast 
agents currently administered, go to uninteresting subject regions or 
become eliminated. Nanotechnology has open then a new era in the 
contrast agent field, optimizing the detection by imaging of the contrast 
agent and eventually combining the diagnostic and therapeutic 
potentials by adding a therapeutic agent to the same nanotechnological 
platform, to produce the new generations of  “theragnostic agents”. 
Figure 1.7 presents some of the most commonly used nanoparticle 
formulations. Solid nanoparticles (or powders) may be produced of 
varying sizes, by the spray-drying method, allowing for the encapsulation 
of drugs and contrast agents for oral delivery, in most cases. To this end 
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normally, poli-lactic-glutamic nanoparticles (PLGA) are used for oral or 
rectal administration [55]. 
Lipid nanoparticles, liposomes [56, 57] and micelles [58], provide 
excellent platforms to administer combinations of contrast agents and 
therapeutic principles, in intravenous administrations. In this thesis, I will 
illustrate this aspect combining the use of a novel iron-oxide nanoparticle 
with an anti-inflammatory agent, to obtain strong theragnostic agent 
with anti-inflammatory and antitumoral effects. 
Finally, the use of graphene structures has recently been added to the 
array of nanotechnology platforms, to administer contrast agents, 
combining imaging probes and therapeutic agents. Gd(III) atoms have 
been included in fullerenes and carbon nanotubes. However, the 
magnetic properties of these arrangements and their use as contrast 
agents, remains nowadays insufficiently characterized. In this thesis, I will 
describe the magnetic properties of single-wall and multi-wall carbon 
nanotubes as novel nanoprobes for anisotropic MRI. 
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Figure 1.7. The development of recent nanotechnology approaches has 
driven the creation of new families of imaging contrast agents. Classic 
contrast agents as Gd(III) DOTA are now competing with newer, more sensitive 
and more selective, contrast agents based on PLGA nanoparticles (top left), SPIO 
nanoparticles (top center), Lipid Nanoparticles (top right), Quantum Dots 
(bottom left), Dendrimers (bottom center)s or Graphene structures (bottom 
right). 
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Chapter 2 
Nanotex: a novel superparamagnetic 
nanoparticle to image tissue perfusion by 
Magnetic Resonance Imaging 
 
Chapter 2 describes the preparation, 
characterization and evaluation of a novel 
superparamagnetic nanoparticle as an 
advanced, low adherence, superparamagnetic 
contrast agent for Magnetic Resonance Imaging 
of tissue or tumoral perfusion. 
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2.1. Introduction 
The effect of chelated paramagnetic metals as contrast agents in MRI has 
been known since the early 1980’s [22]. Gadolinium, a paramagnetic 
metal of the rare earth series, became the optimal candidate because its 
large magnetic moment, seven unpaired electrons and their long 
electronic relaxation time. However, its significant toxicity when 
administered free precluded its use in the clinic. In 1983, the first 
gadolinium chelate which eliminated the toxic effect of free gadolinium 
was proposed, opening the opportunity to use it as a safe contrast agent 
in MRI [11, 59]. Other gadolinium chelates, based on the cyclen structure 
followed soon after [11, 60]. However, the need of high doses of these 
paramagnetic agents to obtain significant MR contrast, and the recent 
appearance of toxic responses in some chelates [61], challenged their 
use. In the late 80’s,  new generations of more efficient contrast agents 
based in the use of superparamagnetic nanoparticles, were described 
[47]. The first nanoparticles consisted of a nucleus of magnetite (Fe3O4) 
covered by a layer of free or cross-linked dextran. Some of these 
nanoparticles, as Endorem or Resovist, were shown to depict high 
relaxing power, be devoid of significant toxic effects and thus, became 
commercialized and used in the clinic soon after [62, 63]. However, the 
first generation of superparamagnetic nanoparticles was not free from 
adverse effects. Despite their enormous relaxing power, these 
nanoparticles became trapped by the reticuloendotelial system and 
because of the dextran cover, became unselectively adsorbed over 
capillary and tissue surfaces, accumulating in tissues after repeated 
administrations, thus disadvising fast subsequent administrations [64].  
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In this chapter we propose, characterize and evaluate a new 
superparamagnetic nanoparticle maintaining the iron oxide core, but 
covered by a layer of polyacrylic acid. The nanoparticle depicts improved 
T2* relaxation properties, reduced non-specific adherence in capillaries 
and tissues, very low splenic accumulation and adequate T1 and 
T2,relaxation properties, supporting its use as an improved 
superparamagnetic contras agent in MRI, with emphasis in perfusion 
imaging. 
2.2. Materials and Methods 
2.2.1. Preparation of the Iron Oxide Superparamagnetic 
Nanoparticle Nanotex. 
Magnetite (Fe3O4) nanoparticles were prepared by the co-precipitation 
[65] of Fe3+ and Fe2+ ions (molar ratio 2:1, total Fe 0.3M, 25 0C) with 
ammonia (29.6%, pH:10) in an inert atmosphere, followed by 
hydrothermal treatment (80 0C, 30 min) [66]. The magnetic nanoparticles 
were washed several times with deionized water and ethanol, and dried 
at 70 0C in a furnace for subsequent treatment. For the binding of 
polyacrylic acid (PAA), 100 mg of Fe3O4 nanoparticles were first mixed 
with 2 ml of buffer A (0.003 M phosphate, pH 6) and 0.5 ml of 
carbodiimide solution (0.025 g·mL-1 in buffer A). After being sonicated for 
10 min, 2.5 ml of PAA solution (60 mg·mL-1 in buffer A) were added and 
the reaction mixture sonicated (Ultrasonic bath, JP Selecta, Abrera, ES) 
for an additional 30 min. Finally, the PAA-coated Fe3O4 nanoparticles 
were recovered magnetically, washed with water twice and dialyzed 
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against a buffer saline solution. In the following, the resulting 
nanoparticle is named Nanotex. 
2.2.2. Magnetic Relaxation Properties.  
The evaluation of magnetic relaxation properties (T1, T2 and T2*) of 
Nanotex was investigated using both, a Bruker Minispec system (Bruker 
Biospin, Ettlingen, DE) at 1.5 Tesla, a clinical field strength, and with a 
Bruker Pharmascan scanner (Bruker Biospin, Ettlingen, DE) operating at 7 
Tesla [67]. 
T1 values at 1.5 T were determined with the progressive saturation 
sequence [68], TE: 10 ms, TR: 70-12000 ms (at least 9 values). T1 values at 
7T were obtained using a spin-echo sequence with TE: 12.62 ms, TR: 150-
6000 ms (7 echoes) using coronal sections (1.5 mm) across a collection of 
capillaries (1mm diameter) containing, each one, increasing 
concentrations of Nanotex. Acquisition conditions were; FOV (Field of 
View) 30 mm, matrix size 256x256 pixels. T1 values (mean ± SD) were 
determined in T1 maps calculated by fitting pixel by pixel the expression 
 (where S is the signal value for each TR and S0 the 
value for TR=0) using the in-house developed program MyMap Analyzer 
running in a MatLab environment (The Mathworks, Natick, 
Massachusetts, USA). T1 values are expressed in ms as mean ± standard 
deviation. 
T2 values (ms) at 1,5 T were obtained (Minispec, Bruker Biospin, 
Ettlingen, DE) in the same tubes used for T1 measurements, using a spin-
echo sequence (Carr-Purcell-Meiboom-Gill) independent of spin diffusion 
with TR: 9000 s, TE: 10-2000 ms (at least 9 values) [68]. T2 values at 7T 
were determined (mean ± SD) using a spin-echo sequence with TR: 5000 
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ms, TE: 12-600 ms (50 echoes), FOV 30 mm, matrix size 256x256 pixels. 
T2 maps were calculated from the collection of T2 weighted images by 
non-linear fitting of the pixel intensities to the expression 
 (where S is the signal value for each TR and S0 the value for 
TR=0). 
T2* maps at 7T were acquired from coronal sections (1,5 mm) across a 
collection of capillaries (1mm diameter) containing increasing 
concentrations of Nanotex, using a gradient echo sequence [68], TR: 300 
s, TE: 2.3-40 ms (at least 9 values), a FOV of 30 mm, matrix size of 
256x256 and a coronal section of 1.5 mm [68]. T2* values were calculated 
from the T2* maps by non-linear fitting of the pixel intensities to the 
expression  (where S is the signal value for each TR and 
S0 the value for TR=0) using the in-house developed program MyMap 
Analyzer running in a MatLab environment (The Mathworks, Natick, 
Massachusetts, USA). T2* values are expressed in ms as mean ± standard 
deviation. 
2.2.3. Citotoxicity 
The in vitro toxicity of Nanotex in C6 glioma cell cultures was investigated 
measuring the metabolic reduction of MTT (tetrazolium salt) to 
formazan, a process which evaluates the potential red-ox and the 
intracellular oxidative metabolism. The cellular viability is directly 
associated to the reduction of MTT to formazan, a reaction which only 
occurs in living cells [69]. MTT test was implemented for C6 incubations 
with increasing concentrations of Nanotex, and the results expressed as a 
percentage of cell survival.  
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2.2.4. Splenic Accumulation 
Splenic accumulation [70] of Nanotex in vivo was determined by 
measuring T2* values in spleens isolated from CD1 mice sacrificed one 
hour after intravenous injection of Nanotex (15 micromol Fe/kg body 
weight). This dose corresponds to the amount recommended for use in 
the clinic by commercial nanoparticle manufacturers and has served as a 
reference dose here. The spleens were isolated from mice killed by 
cervical dislocation and placed in six well Plexiglas plates allowing for 
construction of the corresponding T2* maps. The resolution and 
sensitivity achieved with this method allowed for very precise 
measurements of T2* in spleen ex vivo, not achievable for the spleen in 
vivo. 
2.2.5. Pharmacokinetics 
To investigate the in vivo pharmacokinetics of Nanotex by MRI, we 
obtained T2* weighted images and the corresponding T2* maps of coronal 
sections across the thorax and abdomen of Swiss CD1 mice, before 
intravenous administration of Nanotex and at increasing times after its 
administration (1, 3, 6, 24, 48, 168 h) [71]. The Nanotex nanoparticles 
were administered intravenously as an aqueous solution at a dose of 15 
micromol Fe/kg body weight. This dose corresponds to the amount 
recommended in the clinic by commercial nanoparticle manufacturers of 
Endorem or Resovist, and has served as a reference dose here. 
2.2.6. Use of Nanotex in MRI Perfusion Imaging 
Microvascular perfusion was assessed by monitoring kinetically by MRI 
the passage of a contrast agent “bolus” through a body section (bolus 
tracking method) [72, 73]. Basically, after a very fast injection, the 
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contrast agent solution moved through the vasculature as a “bolus”, 
maintaining the initial concentration of the injected solution in the 
microvasculature, at least during its first passage through each tissue. 
When the MR imaging plane is reached by the bolus, a decrease in the 
image intensity is measurable by MRI that is proportional to the 
concentration of the injected agent [74]. 
To investigate tissue and tumoral perfusion we used the C6 glioma model 
[75]. Briefly, male adult Sprague-Daweley rats received 106 C6 cells in the 
caudate nucleus. Tumors developed during the next two weeks until the 
MRI perfusion measurement took place. The kinetics of contrast agent 
passage across the imaging plane, where acquired using a Bruker Biospec 
scanner (7T, Bruker BIOSPIN, Ettlingen, DE) with an echoplanar sequence 
(EPI), with TE:10.32 ms and TR: 277,51 ms (150 T2* images). A bolus of 
contrast agent (250 μL of Nanotex, 90 μmoles Fe/Kg) was injected 
intravenously in the tail vein of Sprague-Dawley adult male rats (n= 6) 
carrying implanted C6 glioma 10 seconds after the beginning of the 
acquisition sequence 
The kinetics of contrast agent passage through the imaging plane, 
approaches a gamma function with an initial portion, a point of 
maximum intensity and a decrease until disappearance. The area under 
this curve represents the cerebral blood volume (CBV; ml/100g) in the 
imaging plane. The time between the beginning of passage and the 
maximum concentration is the mean transit time (MTT), a magnitude 
that measures the time (s) in which half of contrast bolus has passed 
through the section. Finally, the cerebral blood flow (CBF) is calculated as 
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the CBV/MTT ratio, representing blood flow [(ml/100g)/min] through the 
investigated cerebral section in a pixel by pixel manner [74]. 
The perfusion values (CBV, CBF and MTT) were obtained using the home 
made program MyMap Analyzer by the adjustment of the increment of 
T2* relaxivity (Δr2*) to a gamma function. With this adjustment, the 
perfusion values are given by the equations: 
 Eq. 2.1 
 
Eq. 2.2 
 Eq. 2.3 
2.2.7. Evaluation of Nanotex as a CT Contrast Agent 
Due to the high electron density of the iron core of Nanotex, we 
evaluated its potential use as contrast agent in CT (INVEON PET-SPECT-
CT, Siemens AG, DE). The CT images were taken with a voltage of 80 kV 
and a current of 500 μA. The exposure time was 220 ms, acquiring 180 
projections with a FOV of 57.2 x 57.2 mm. We obtained an image of X 
Rays of different concentrations (25%, 50%, 75% and original sample) of 
Nanotex and compared it with that of a commercial CT contrast agent, 
Ultravist (300 mg / mL, Bayer, DE) dissolved in water, placed closely in 
parallel wells of a 96 well plate. The X Ray densitometries obtained were 
analyzed using the freely available ImageJ package 
(http://rsbweb.nih.gov/ij/, National Institutes of Health, Bethesda, 
Maryland, US). 
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2.3. Results 
2.3.1. Preparation and Characterization 
The study of the magnetic relaxation behaviour constitutes an essential 
requirement in the characterization of a new contrast agent for Magnetic 
Resonance Imaging. Figure 2.1 summarizes the relaxation properties of 
solvent water in Nanotex suspensions for T1 (A, C) and T2 (B, D) at 1.5 
Tesla in water (top panels) and serum (bottom panels), in concentrations 
ranging from 0 to 0.05 mM Fe.  
 
Figure 2.1. Magnetic relaxation properties of water in Nanotex 
suspensions of increasing nanoparticle concentration at 1.5 Tesla. T1 (A, 
C) and T2 (B, C) relaxation in water (top) or fetal bovine serum (bottom), in 
concentrations ranging from 0 to 0.05 mM Fe. 
Nanotex reduces the values of the different water relaxation times, T1 or 
T2 in a concentration dependent manner. As expected for a 
superparamagnetic nanoparticle, the reduction is much larger in T2 than 
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in T1.The highest concentration tested reduced T1 water from 3200 ms to 
2600 ms, and T2 from 2500 ms to 600 ms, respectively. . In the case of 
serum, a reduction of T1 from 1800 ms to 1600 ms, and T2 from 1000 ms 
to 700 ms is observed. The Nanotex effect on T2 remains higher than in 
T1, but the magnitude is smaller than that observed in pure water. This 
may be due either to a reduction in the effective amount of water 
available for relaxation with the nanoparticle in serum (solvation of 
proteins, carbohydrates and ions in plasma) or to reduction of the free 
nanoparticle concentration in water due to binding to plasma 
components. 
 
Figure 2.2. Magnetic relaxation properties of water in Nanotex 
suspensions of increasing Fe concentration at 7 Tesla. T2 (A, C) and T2* 
(B,D) relaxation values at 7 Tesla in water (top) and fetal bovine serum (bottom) 
of Nanotex suspensions in concentrations ranging from 0 to 0.05 mM Fe. Values 
represent the mean ± SD of the pixels from a coronal plane taken across the 
capillaries for each condition. 
Nanotex reduced the T2 value of water from 300 ms to 220 ms in water 
and from 159 ms to 133 ms in serum, respectively. T2* reductions by 
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Nanotex were to 18 ms in water and 10 ms in serum, respectively.  Again, 
the reductions observed in T2 and T2*, were smaller in serum than in 
water, supporting the association of the nanoparticle to serum 
components in a way that decreases its relaxing capacity. These results 
were compared with those obtained with a commercial nanoparticulate 
contrast agent, Endorem (11.2 mg Fe / mL, Guerbet, FR) under the same 
conditions (Table 2.1).  
Table 2.1. Comparison of r1, r2 and r2* relaxivity values of Nanotex and 
Endorem suspensions in water and serum measured at 7 Tesla. 
 
 r1 (mM-1·s-1) a) r2 (mM-1·s-1) a) r2* (mM -1·s-1) a) 
Nanoparticle Water Serum Water Serum Water Serum 
Endorem 1.1044 0.922 103.55 66.49 298.88 159.93 
Nanotex 0.5524 0.4951 88.971 94.163 97.334 119.78 
a)Relaxivity values were determined at 22 0C as the slope of the linear increase in 1/T1, 
1/T2 or 1/T2* values with Nanotex or Endorem concentrations (0 - 0.05 mM [Fe]). 
 
Table 2.1 summarizes the comparative relaxivity values measured in 
serum or water. The r1 and r2* relaxivity values of Nanotex were smaller 
than those of Endorem in water and serum, but r2 of Nanotex reached a 
higher value than Endorem in serum.  These results imply a significant 
advantage of Nanotex over Endorem when using imaging sequences 
weighted in T2 in vascular imaging. 
2.3.2. Toxicity Evaluation in Cell Cultures and in vivo 
Rodent Models 
An evaluation of the potential cytotoxic effects of a new contrast agent is 
necessary to support its safety profile and potential applications in the 
clinic. The contrast agent should present reduced or absent cytotoxicity 
35 
 
and reduced tissue accumulation, allowing for multiple administrations 
without significant accumulations in specific tissues as the spleen.  
Figure 2.3 shows the results of MTT reduction from C6 cells versus 
increasing concentrations of Nanotex or Endorem after 1 hour (A) and 24 
hour (B) of incubation.  Changes in cell viability are hardly detectable 
throughout the concentration range investigated, suggesting negligible 
cellular toxicity of Nanotex or Endorem in glioma C6 cell cultures. A 
positive control (a cytotoxic concentration of hydroxylamine) was 
employed to confirm that viable cells can be killed, and that cell killing 
and survival can be detected by the MTT reduction assay. 
 
Figure 2.3. Comparative study of cytotoxicity of Nanotex and Endorem. 
Effect of increasing concentrations of Nanotex and Endorem on C6 cell viability 
detected by MTT reduction assay, after 1h (left) or 24h (right) incubation. 
Hydroxylamaine was used as a toxic control. 
 
The next step in the development a new contrast agent development is 
to assess the in vivo toxicity. To this end, CD1 mice were injected with 15 
micromol Fe/kg body weight of Nanotex or Endorem. This dose 
corresponds to the recommended dose in the clinic by commercial 
Endorem manufacturers and has served as a reference dose here. Figure 
2.4 shows representative results of a study of accumulation of these 
36 
 
nanoparticles in spleens isolated from different animals receiving either 
Nanotex (n=3), Endorem (n=2) or saline (n=1). 
Nanotex accumulation was then investigated through the analysis of T2* 
relaxation in ex vivo spleens of CD1 mice one hour after the injection. 
Accumulation of the nanoparticles in this organ may cause a spleen 
failure and represent a clear symptom of toxicity. The resolution and 
sensitivity achieved with this ex vivo MRI method allows very precise 
measurements of T2* in spleen, not achievable for the mouse spleen 
under in vivo conditions. 
 
Figure 2.4. Splenic accumulation of different iron oxide nanoparticles as 
detected by T2* weighted MRI. Six spleens (A-F) from mice, obtained one 
hour after the intravenous injection of Endorem (A, B), Nanotex (C, D, E) or 
saline (F). The doses of both contrast agents were 15 micromol Fe/kg body 
weight. 
Figure 2.4 shows representative results of this study of Fe accumulation 
from injected nanoparticles in the spleen of two animals injected with 
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Endorem, three animals injected with Nanotex and a control. Note that 
the spleens from mice receiving Endorem or Nanotex appear darker than 
the control mouse receiving saline, as expected for nanoparticle 
accumulation. Moreover, the spleens receiving Endorem appear darker 
than those receiving Nanotex, revealing relatively lower accumulation of 
Nanotex than of Endorem. 
Table 2.2 provides the quantitative T2* values of isolated spleens before 
and one hour after intravenous injection of Nanotex or Endorem (15 
micromol Fe/Kg body weight). Notably, Nanotex did not induce a 
significant decrease in splenic T2*, suggesting a very low or non-existent 
splenic accumulation and negligible biological adherence. However, 
Endorem induce a decrease in splenic T2* comparable with values 
measured with another commercial nanoparticle, Resovist (Schering, DE), 
which induces a splenic T2* value of 2.11 ± 0.2 ms.  
Table 2.2. Splenic accumulation of Nanotex and 
Endorem one hour after intravenous 
administration of the nanoparticles as detected by 
the splenic T2* value. 
 
Condition Splenic T2* (ms)a) 
Control (saline) 4.78 ± 0.20 
Nanotex  4.26 ± 0.26 
Endorem  3.51 ± 0.16 
a) T2* values were determined ex vivo, at 7T (Bruker Pharmascan), 
using the gradient echo sequence in spleens isolated from CD1 mice 
either before or 1h after nanoparticle administration. 
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During the in vivo studies no appreciable external toxicity signs were 
observed after the administration of Nanotex, including the 
administrations of doses double than those recommended commercially. 
In addition, Nanotex was found compatible with the protocol of 
anaesthesia used (isoflurane 1-2%), without mortality detected due to 
the nanoparticle in any of the investigated healthy animals (n= 12). 
More specifically, the administration of Nanotex did not induce 
significant changes in respiratory or heart rate, no external symptoms of 
hepatotoxicity such as yellowish fur, hair or eyes, bald spots,, hyper- or 
hypoactivity (sleepiness), aggressiveness, food and water intake 
disorders, hemiparesis or hemiplegia. 
The residence time of the contrast agent in the body is another aspect 
that needs to be characterized in a new contrast agent. It is preferable a 
contrast agent with short residence time, being eliminated from the body 
rapidly, than a contrast agent with long residence time, thus disadvising 
repetitive accumulations.  
 
Figure 2.5. Representative T2* MRI of mouse liver in vivo before (A) and 
after Nanotex (B) or Endorem (C) administrations. Representative T2* 
weighted images (left) of thorax and abdomen of mice and T2* maps obtained 24 
h after intravenous administration of Nanotex (center) and Endorem (right) with 
a clinical doses of 15 micromol Fe /kg body weight. 
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Figure 2.5 shows representative T2* weighted images across the 
abdomen and thorax of a control mouse before the administration of 
nanoparticle suspensions (left), or T2* maps obtained 24 h after 
intravenous administration of the same dose of Nanotex (center) or 
Endorem (left). The T2* map (Figure 2.5 center) shows significantly lower 
values of T2* in the livers of animals treated with Nanotex or Endorem, 
confirming previous results. 
Figure 2.6 summarizes the results of T2* images acquired at different 
times after , after intravenous administrations of single dose (15 
micromol Fe/kg body weight) and double dose (30 micromol Fe/kg body 
weight) of Nanotex, compared to those obtained after the administration 
of the same doses of Endorem. Nanotex induced a slight decrease in 
hepatic T2*, with a fast decline followed by rapid clearance from hepatic 
tissue. Meanwhile, Endorem depicted a higher decrease in T2* but a 
significantly slower clearance kinetics. Interestingly, the single dose of 15 
micromol Fe/kg body weight Nanotex was cleared completely in 
approximately 24 hours with an approximately mean half-life (t1/2) of 
hepatic elimination of 10 h. This mean half-life is significantly shorter 
than that of dextran coated nanoparticles as Endorem, revealing a lower 
vascular and tisular adherence and allowing for repetitive administration 
protocols at shorter time intervals. 
Notably, the administration of  Nanotex at a dose twice the one 
recommended (30 micromol Fe/kg body weight) demonstrated a 
significantly improved relaxation effect in the liver, only slightly smaller 
than that obtained with Endorem (15 micromol/Kg body weight), without 
appreciable changes in the rapid Nanotex elimination rate from liver.  
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Figure 2.6. In vivo pharmacokinetics of hepatic clearance of Nanotex 
and Endorem after i.v. nanoparticle administrations. Relative changes in 
hepatic T2* after injection of a single dose (15 micromol Fe /kg body weight) and 
double dose (30 micromol Fe/kg body weight) of Nanotex in the tail vein of mice 
are compared with those induced by Endorem (15 micromol Fe/Kg body weight). 
The results represent, mean and standard deviation of four animals investigated 
after administration of the contrast agent. The region between 0 and 6 hours is 
amplified in the insert for improved visualization of the enhancement effect. 
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Notably, the administration of the double dose showed no adverse 
symptoms and all mice survived the study. 
In summary, we have shown that Nanotex depicts appropriate relaxation 
properties, lack of toxic effects and optimal pharmacokinetic properties 
improving those of Endorem. Taking together, these properties make 
Nanotex a very competitive superparamagnetic nanoparticle in 
comparison with the ones currently available commercially.  However it 
remains important to demonstrate a specific application in MRI, where 
its advantages are more evidently proven in comparison with those of 
the earlier generation of paramagnetic and superparamagnetic 
nanoparticles. This is addressed in the next section.  
2.3.3. Use of Nanotex in Perfusion Imaging 
To this end we selected the MR imaging of tumoral perfusion, an 
advanced protocol used in the clinic with either gadolinium or iron based 
contrast agents. We set up the glioblastoma multiform model obtained 
after implantation of C6 cells, and investigated comparatively if Nanotex, 
Endorem and Gd(III)DTPA could provide improved information of the 
performance of the neoangiogenic vasculature of glioblastoma. 
Figure 2.7 illustrates the determination of cerebral perfusion parameters 
using Magnevist, Resovist or Nanotex in rats carrying implanted C6 glial 
tumours. Briefly, the figure illustrates the fitting of the perfusion gamma 
function (red) to the kinetics of “bolus” passage of the different contrast 
agents (blue). 
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Figure 2.7. Comparative study of tumoral perfusion by the “bolus 
tracking” method in the C6 glioma model using paramagnetic or 
superpamagnetic agents. A: Gd(III) DTPA (Magnevist, Bayer, DE), B: Resovist 
(Bayer, DE) and C: Nanotex (Nanotex, ES). 
Note that superparamagnetic Nanotex showed a similar behaviour to 
that of paramagnetic Magnevist, a behaviour not observed with the 
commercial superparamagnetic nanoparticle Resovist. Nanotex 
demonstrates a fast transit time and a virtually complete perfusion 
recovery after i.v. injection, revealing that Nanotex behaves similarly to 
Magnevist, does not remain fixed in the neovasculature as Resovist and 
does not adhere, nor significantly interacts with the endothelium of the 
glioma neovasculature. 
Table 2.3 shows CBF [(ml/100g)/min], CBV (ml/100g) and MTT (s) values 
of Nanotex (15 micromol Fe/kg body weight) in the brain of rats carrying 
implanted C6 tumours, as calculated from the non-linear fittings to the  
gamma function representing the transit of the contrast agent. The 
results are compared with another nanoparticle, Resovist, and with 
Magnevist, a contrast agent based in Gadolinium chelates used as 
contrast agent in MRI.  
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Table 2.3. Cerebral perfusion parameters determined by the MRI bolus 
tracking method using Magnevist, Resovist or Nanotex (15 micromol 
Fe/Kg body weight). 
 
 Value (mean±sd)a) 
Perfusion parameter Nanotex Magnevist Resovist 
CBF (mL/100g/min) 22.86±4.62 196.97±108.01 69.79±40.01 
CBV (mL/100g) 1.41± 0.06 17.97±17.75 9.72±6.92 
MTT (s) 3.55± 1.00 5.69±2.21 8.45±4.61 
a) Perfusion values were determined in vivo at 7T (Bruker Pharmascan)from CD1 mice after 
the injection of Nanotex, Magnevist or Resovist bolus. 
 
Nanotex depicted a shorter mean transit time in tissue than Magnevist 
and Resovist, probably due to the charged polyacrylic acid cover which 
avoid the aggregation of nanoparticles between them and with the 
capillary. Also, the cerebral blood volume is smaller for Nanotex 
indicating that this nanoparticle does not extravasculate from the blood 
to the surrounding tissue. On these grounds, Nanotex displays very 
favourable first passage kinetics and recovery through the cerebral 
microvasculature. 
2.3.4. Use of Nanotex as Contrast Agent in CT images. 
Due to the ferric nucleus we thought that Nanotex could be a good 
candidate as contrast agent in CT images. Figure 2.8 shows the results of 
the analysis of Nanotex as a X Ray contrast agent. To evaluate this fact, 
Nanotex was compared with a commercial X Ray contrast agent (Figure 
2.8. A) finding that the signal produced by Nanotex was smaller than  
Ultravist. The posterior analysis with ImageJ indicates that Nanotex 
shows a signal enhancing effect but smaller than the commercial contrast 
agent Ultravist (Figure 2.8. B). 
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Figure 2.8. Comparison of Nanotex and Ultravist (Bayer Schering, DE) as 
CT contrast agents. X Ray images of different concentrations of Nanotex (A, 
left column) shows a contrast effect but lower than a commercial contrast 
agent, Ultravist (A, right column). B shows the values of intensity at different 
concentrations and the adjustment of data to a line showing the more intense 
effect of Ultravist as X-rays contrast agent. 
2.4. Discussion 
We developed a novel superparamagnetic nanoparticle for magnetic 
resonance imaging with an inorganic core diameter smaller than 15 nm 
and a negative surface electrical charge at neutral pH, two important 
features that contribute importantly to its intrinsic low vascular and 
tissular adherence in vivo. The combination of these properties 
determines an excellent pharmacokinetic profile with very reduced 
toxicity and optimal vascular transit times. The new nanoparticle shows 
only transient retention in the liver, without significant bioaccumulation, 
thus allowing repeated administration protocols, compatible also with 
the imaging of hepatic lesions. Reduced accumulation and efficient 
elimination may permit the frequent repetition of Magnetic Resonance 
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Imaging studies along time, at much short intervals than those required 
with currently available commercial [76, 77]. 
The lower tissue adherence of Nanotex, in comparison with Endorem or 
Resovist, merits further analysis. Since the iron core is very similar, the 
difference must necessarily rely in the polyacrylic acid coating. We 
believe this coating endows Nanotex with a negatively charged surface at 
neutral pH, favouring repulsion with other Nanotex particles and with the 
negatively charged phospholipid headgroups and proteins from the 
surface of endothelial cells. These repulsive interactions are not present 
in the commercial nanoparticles coated with dextran or cross-linked 
dextran, which easily adsorb over endothelial surfaces or interact with 
neighbouring particles most probably through hydrogen bonding. This 
non-specific interaction may favour the formation of aggregates of 
Resovist and Endorem with blood cells or within themselves, difficulting 
their passage through narrow capillaries, a circumstance that would not 
happen with the negatively charged Nanotex. 
The comparison of the magnetic properties of Nanotex with commercial 
nanoparticles as Endorem or Resovist shows, however, less favourable r1 
and r2 magnetic relaxivity properties for Nanotex [49]. Nevertheless, 
Nanotex T2 relaxation remains adequate for excellent in vivo imaging of 
the liver and hepatic pathologies. Moreover, Nanotex r2* relaxivity is 
improved with respect to the commercial nanoparticles, favouring an 
advantageous use of our nanoparticle with T2* imaging based methods, 
such as perfusion MRI. In this sense, the excellent r2* values of Nanotex, 
add to its low adherence properties to configure very clean first passage 
kinetics, returning completely to baseline, a circumstance not observed 
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with commercial nanoparticles and only attainable previously with 
Gd(III)DTPA complex. This collection of properties makes Nanotex an 
ideal candidate to be used in tissue and tumoral perfusion assays in vivo 
with Magnetic Resonance Imaging, supporting a potential commercial 
development. A patent has been filed protecting the nanoparticle and its 
applications [78]. 
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Chapter 3 
Magnetoliposomes loaded with ω-3 
Polyunsaturated Fatty acids as anti-
inflammatory theragnostic agents 
 
Chapter 3 describes the development of a new 
theragnostic formulation based in liposomes 
containing both, a -3 polyunsaturated fatty 
acid and an imaging biomarker. The efficacy of 
this new formulation is validated using a variety 
of imaging techniques and with different animal 
models of colonic inflammation and cancer. . 
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3.1. Introduction 
Inflammatory lesions are associated to the most prevalent and morbid 
pathologies including atherosclerosis [79], neurodegeneration [80] 
diabetes or obesity [81] and cancer [82], among others. Decreases in the 
inflammatory phenotype are known to improve the disease progression 
and the patient´s quality of life, as well as to favour a better recovery 
[83]. With this aim, a variety of anti-inflammatory drugs have been 
proposed as adjuvant therapies for the different diseases, including 
mainly steroidal or non-steroidal treatments [84]. In all cases, anti-
inflammatory therapies demand the use of relatively large doses of the 
active drugs and inevitably end up developing, sometimes too early, a 
collection of adverse secondary effects that preclude further treatment 
[85]. On these grounds, methods to improve the efficiency of anti-
inflammatory drug delivery to the lesion, therefore increasing its 
selectivity and efficacy, entail considerable interest as well as potentially 
vast applications in a wide spectrum of diseases. 
Liposomes have been proposed previously as novel nanotechnology 
formulations to improve drug delivery to a variety of inflammatory 
diseases [86, 87]. Targeting of the inflammatory region may be achieved 
using either active or passive approaches. Active targeting involves the 
use vectorial reagents embedded in the liposomal membrane that 
recognize epitopes of the target tissue [88]. Passive targeting refers to 
the passive accumulation of the liposomes in the inflamed regions 
because of their increased capillary permeability and limited clearance 
[89]. In both cases it becomes difficult to visualize if the liposomal 
preparation has arrived to the target tissue and many times, only indirect 
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measurements of inflammation provide an index of the anti-
inflammatory effect. It would become then very useful, to visualize 
directly and non-invasively the presence of the drug loaded liposomes in 
the lesion. Liposomes are optimal structures for this purpose, since they 
can be prepared to contain in their lumen, in addition to the anti-
inflammatory drug, a variety of imaging indicators either radioactive, 
fluorescent or superparamagnetic. This approach is known as image 
guided drug delivery [90], representing currently the most promising 
strategy to diagnose and treat inflammatory diseases. 
Recently, important anti-inflammatory effects have been reported using 
preparations of omega-3 fatty acids [91-94], a kind of long chain 
polyunsaturated fatty acids (PUFAs) mainly present in fish oil and used as 
dietary supplements. Omega-3 PUFAs allow prolonged anti-inflammatory 
treatments without the appearance of the deleterious secondary effects 
of alternative steroidal or non-steroidal drugs [95]. 
In this chapter we report a successful protocol to encapsulate -3 
polyunsaturated fatty acid ethyl ester (PUFA-EE) in liposomal 
preparations containing, in addition, either the Nanotex 
superparamagnetic nanoparticle or the rhodamine-100 dye. These 
advanced theragnostic preparations maintain in its integrity the 
therapeutic potential of free ω-3 PUFA-EE, potentiated with important 
multimodal imaging capabilities. We demonstrate their anti-
inflammatory effects in vivo, in animal models of colonic and oncologic 
inflammation. 
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3.2. Materials and Methods 
3.2.1. Preparation and Characterization of Liposomes 
Lipid hydration and extrusion method 
Liposomes were prepared essentially using the film hydration method 
[96]. Briefly, 20 mg of L-α-phosphatidylcholine (Avanti Polar Lipids Inc., 
Alabaster, Alabama, USA) were dissolved in 2 mL of chloroform (Merck, 
Darmstad, DE). The solution was placed in a round flask and subjected to 
rotary evaporation (Heindolph Instruments, Schwabach, DE) for sixty 
minutes, 280 rpm, 474 mBar and 40 0C. The lipid film formed after 
chloroform evaporation was further rotated under the same conditions 
to remove chloroform traces. Then, the dried lipid lecithin film was 
rehydrated with 5 mL of water (containing or not the active principle or 
imaging probe) and rotated 60 minutes at atmospheric pressure and 50 
0C. This process generates a heterogeneous suspension of liposomes of 
different sizes containing or not the active principles and imaging probes 
in their lumen as delivered with the hydration buffer. To homogenize the 
size distribution, the liposomal suspension was extruded eleven times 
(Northen Lipids, Burnaby, CAN) under nitrogen pressure through a 200 
nm membrane (Whatman, GE Healthcare, Fairfield, Connecticut, USA) 
maintaining the temperature at 50 0C. The resulting suspension 
containing homogenous liposomes, loaded or not with the selected 
imaging agent and ω-3 PUFA-EE, was stored at 4 0C until further 
utilization. A schematic description of the process can be seen in Figure 
3.1.  
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Figure 3.1. Preparation of liposomes. Liposomes are prepared from egg yolk 
lecithin, containing or not ω-3 PUFA-EE, Nanotex or rhodamine-100 by the film 
hydration method [96]. A solution of chloroform and lecithin is rotated under 
vacuum to remove chloroform and deposit a thin lecithin film covering the 
round bottom flask. Hydration of this film with aqueous buffer results liposomes 
of different sizes and different number of layers. Nanotex, ω-3 PUFA-EE or 
rhodamine-100 may be added to the buffer, resulting in their intraluminal 
encapsulation after liposomal formation. Some residual Nanotex, ω-3 PUFA-EE 
or rhodamine-100 may remain in the extraliposomal space. Repeated extrusions 
(x11), result in crude homogeneous suspensions of liposomes loaded or not with 
added components in their lumen, but also present in the extraliposomal space. 
These may be removed later after a purification process, normally based in size 
exclusion chromatography or differential centrifugation through filters of 
controlled pore size. 
We prepared liposomes encapsulating either suspensions of (i) buffer 
alone, (ii) Nanotex (25 mg Fe/mL, Solutex S.L., Alcobendas, ES) as MRI 
detectable probe, (iii) Nanotex and ω-3 PUFA-EE (0.1% aqueous volume, 
Solutex S.L., Alcobendas, ES) as theragnostic anti-inflammatory agents 
detectable by MRI, or (iv) Nanotex with rhodamine-100 chloride (10 
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mg/mL, Sigma Aldrich, Barcelona, ES) as a novel agent detectable by 
hybrid fluorescence and MRI. 
Transmission Electron Microscopy 
Transmission electron microscopy (TEM) images were acquired in a JEOL 
JEM1010 100 kV (JEOL Ltd., Tokyo, JAP) from samples of empty 
liposomes, Nanotex and liposomes loaded with Nanotex, stained with 
uranil acetate [97]. 
Dynamic Light Scattering 
The size of liposomes was measured by Dynamic Light Scattering (DLS, 
DynaPro MS/X (Wyatt Inc., Dernbach, DE) essentially as described in refs. 
[98, 99]. A dilution 1:10 of the original samples in water was placed in a 
quartz cuvette inside the apparatus to perform the light scattering 
measurement. Several dilution steps of the original sample were 
necessary to allow for appropriate intensity of light scattering profile in 
the sample. The presence of Nanotex in the preparations hampered light 
scattering measurements in the corresponding preparations, most 
probably due to the high optic density and reflectance of the solution. 
1H High Resolution Magic Angle Spinning (HRMAS) 
1H HRMAS spectroscopy was performed using a Bruker Avance 11.7 T 
instrument equipped with a High Resolution Magic Angle Spining 
(HRMAS) accessory, interfaced with a Linux driven Paravision IV console 
(Bruker BIOSPIN, Ettlingen, DE). Briefly, samples were dissolved in 25 μL 
deuterated water (99.2% 2H, Apollo Scientific Limited, Stockport, UK) or 
deuterated chloroform (99.8%, Scharlau, Barcelona, ESP) containing 
1mM TSP (trimetil sylil 2, 2’, 3, 3’ tetradeutero sodium propionate) or 1 
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mM TMS (tetramethyl silane, Scharlau, Barcelona, ES) used as chemical 
shift references, placed in 50 μL zirconium rotors and inserted in the 
rotating probe adapted to the magnet. Water suppressed 1H HRMAS 
spectra (40C, 4000 Hz) were acquired using the Carr-Purcell-Meiboom-Gil 
sequence with π/2 pulses, spectral width of 10 kHz, acquisition time of 
0.41 sec, D1= 1 sec, 72 π pulses with a separation time τ = 1 ms and 
processed using 1 Hz exponential line broadening applied in the time 
domain prior to Fourier Transformation [68]. 
HRMAS DOSY (Diffusion-Ordered NMR Spectroscopy) spectra of 
liposomes were acquired in a Bruker AVANCE III of 400 MHz (Bruker 
BIOSPIN, Ettlingen, DE) using a 1H selective probe and NMR tubes of 
5mm. The spin-echo Stejsktahl-Tanner sequence, was used with diffusion 
intervals of 20, 50 and 100 ms and diffusion gradient strengths from 2% 
to 95% of the maximal power of the Z gradient (sixteen increments) [68]. 
Water Relaxivity Measurements 
We investigated the effect of magnetoliposomes on the T1 and T2 
magnetic relaxation properties of the water molecules of the suspension, 
to assess their potential usefulness as imaging agents for MRI detection. 
T1 and T2 relaxation times of magnetoliposomes were investigated in two 
different liposomal samples, containing or not the superparamagnetic 
particle Nanotex (0.5 mg/mL). Dilutions of the original suspensions to 
50% and 25% of the initial concentration were used to generate the 
relaxation vs. concentration profiles. Briefly, T1 and T2 values of all 
samples (37 0C) were measured using the inversion recovery sequence or 
Carr-Purcell-Meiboom-Gill (CPMG) sequences using a Bruker Minispec 
1.5 Tesla (Bruker BIOSPIN, Ettlingen, DE) [67].  
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Fluorescence Properties 
We investigated the fluorescent properties of magnetoliposomes labeled 
with rhodamine-100 chloride both in vitro and in vivo using an in vivo 
IVIS-Lumina system (Perkin Elmer, Waltham, Massachusetts, USA) [100]. 
In vitro and in vivo fluorescence images were acquired using a Green 
Fluorescent Protein filter (GFP, excitation bandpass 445-490 nm, 
emission bandpass 515-575 nm) and sixty seconds exposition. For the in 
vitro studies, three samples of liposomes containing or not the 
nanoparticle (25 mg Fe/mL) and the fluorescent dye (10 mg/mL), at 
different concentrations (18.75 mg Fe/mL, 12.5 mg Fe/mL, 6.25 mg 
Fe/mL for the nanoparticle and 7.5 mg/mL, 5 mg/mL, 2.5 mg/mL for 
rhodamine-100) were placed in 96-well plate and scanned. For the in vivo 
studies, CD1 adult mice (30g body weight) were anesthetized in a 
ventilated chamber with a mixture of oxygen and isofluorane (2%, Isoflo, 
Esteve, Barcelona, ES) and maintained on it during the scanning period. 
Images were acquired as indicated above, before and after the i.p. 
injection (200 L) of the liposomal preparations. 
Ultrafiltration by Centrifugation 
The ultrafiltration method separates the sample in two fractions, 
sediment and ultrafiltrate, by forcing the sample to pass through a filter 
of controlled pore size, using centrifugal force. For this purpose, we use 
molecular size filters with a pass of 300 KDa (Vivaspin 6, MWCO 300 KDa, 
Vivaproducts, Littleton, MA, US). The centrifuge used was J-6B (Beckman 
Coulter, L’Hospitalet de Llobregat, ES) with centrifugation conditions of 
2891 g (3900 rpm, 20 0C, 1 hour). After the centrifugation, the absorption 
spectra (200 – 600 nm) of the sediment and the ultrafiltrate was 
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analysed using multiwall plates in a vertical spectrofluorimeter (Synergy, 
Biotek, Winooski, VT, US).  
3.2.2. In vivo evaluation of anti-inflammatory activity 
Animal Models of Inflammation and Experimental Design 
All animal protocols were approved by appropriate institutional review 
panels and follow the guidelines of National advisory bodies in animal 
welfare.  
A convenient model of colonic inflammation was induced in C56BL6 mice 
through the administration of Dextran Sulfate sodium salt (DSS, Leti, 
Barcelona, ESP) dissolved (3.5%) in the drinking water during 5 days 
[101]. Briefly, three groups of mice (n=6) received DSS treatment for five 
days and were injected in the tail vein (100 μL) with Phosphate Buffered 
Saline (Group 1), Magnetoliposomes (Group 2) and Magnetoliposomes 
containing ω-3 PUFA-EE (Group 3) during the first three days. The body 
weight evolution was followed in each mouse until the fifth day when the 
animals were investigated by MRI. For this purpose, mice were injected 
i.p. with 100 μL of Gd(III)DTPA (0.1M) just before coronal T1 images were 
acquired from the rectal zone of each mouse. Colonic inflammation was 
measured by the width of the rectal wall. After the MRI experiment, the 
administration of DSS was stopped and normal drinking water was 
administered to all mice, following their weight until 10th of study. 
The model of oncologic inflammation was induced in CD1 mice through 
the stereotaxic implantation of approximately 106 C6 glioma cells in the 
caudate nucleus of the mouse brain [102]. Fifteen days after the 
implantation the tumor had proliferated reaching sizes ranging from 0.5 
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to 1.5 cm. Two different treatments were investigated in mice 15th days 
after the implantations: a first group (n=6) received Magnetoliposomes 
with ω-3 PUFA-EE and another group (n=6) Magnetoliposomes without 
fatty acids ester. We investigated additionally a control group (n=6) that 
received no treatment. Treatments were administered intravenously 
(unique doses of 100 L) and the growth of the glioblastoma was 
monitored by MRI obtaining images weighted in T1 and T2. 
Magnetic Resonance Imaging 
All MRI examinations were performed using a 7 Tesla horizontal magnet 
(16 cm bore) interfaced with a Bruker AVANCE III radiofrequency console 
operated through a Linux platform running Paravision V software. 
The colon inflammation model was explored with T1 images using a Multi 
Slice Multi Echo (MSME) sequence, TE=10.643 ms, TR=521 ms, 3 
averages, axial orientation, 22 slices, slice thickness 1.5 mm, interslice 
distance 1.5 mm, field of view 3.8 cm.  
The glioma model was investigated with T1 and T2 images. T2 images were  
acquired using a Rapid Acquisition with Relaxation Enhancement (RARE) 
sequence, TE=14.77 ms, TR=2500 ms, 6 averages, axial direction, 14 
slices, slice thickness 1 mm, interslice distance 1 mm, field of view 2.3. T1 
images were acquired using a Multi Slice Multi Echo (MSME) sequence, 
TE=10.643 ms, TR=350 ms, 3 averages, axial direction, 14 slices, slice 
thickness 1 mm, interslice distance 1 mm, field of view 2.3 cm.  
T1 images were always obtained after the i.p. administration of 100 L of 
Gd(III)DTPA (0.1M, Magnevist, Bayer Schering, Berlin, DE) to enhance T1 
contrast. 
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Positron Emission Tomography 
The evolution of colonic inflammation was also followed by PET/CT. The 
images were taken in a trimodality scanner Inveon (Siemens AG, DE). 
18FDG (11 MBq doses) was administered forty five minutes before the CT 
and PET images were acquired to visualize the distribution of the isotope. 
For the PET acquisition, we acquired 159 interferograms of 128 x 128 
pixels (pixel spacing 0.77 mm, slice thickness 0.796 mm) in a FOV of 
83x130mm. The acquisition lasted fifteen minutes and the reconstruction 
algorithm used was the OSEM2D method with four iterations and 
correction by decay and scattering. The CT images were taken with a 
voltage of 80 kV and a current of 500 μA. The exposure time was 250 ms, 
acquiring 180 projections with a FOV of 83x130 mm. The SUV 
(standardized uptake value) value was determined with the corrections 
for isotope decay and animal weight. 
Statistical Analysis 
Comparisons used the mean and standard deviation of all data from each 
group and the t-student test to assess significance (p<0.05). Statistical 
analysis was done using SPSS software (IBM, New York, NY, US). 
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3.3. Results 
3.3.1. Dynamic Light Scattering and Transmission Electron 
Microscopy 
The process of liposomal preparation originates a suspension of 
liposomes with homogenous size. This size was determined 
experimentally by Dynamic Light Scattering (DLS) and Transmission 
Electron Microscopy (TEM) techniques. 
 
Figure 3.2. Determinations of liposomal size. Top panels: DLS of a 
suspension of empty liposomes (A) and a suspension of liposomes loaded with 
ω-3 PUFA-EE (B). Arrows indicate the size of larger aggregates of free -3 PUFA-
EE (black), eventually moving to the surface of the preparation because of their 
lower density. Some nanometric goticules of -3 PUFA-EE (blue) are observed 
transiently. Bottom panels shows TEM images of empty liposomes stained with 
uranyl acetate (C), free Nanotex superparagmagnetic nanoparticle (D), and 
liposomes loaded with Nanotex (E). Note the presence of extraliposomal 
Nanotex nanoparticles prior to final purification. 
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Figure 3.2 (top) shows representative results of size measurements in 
liposomal preparations containing (2B) or not (2A) ω-3 PUFA-EE as 
performed with DLS. DLS analysis of liposomes without ω-3 PUFA-EE 
showed 200 nm diameter vesicles, corresponding well with the 200 nm 
filter used in the extrusion. The liposomal preparations containing ω-3 
PUFA-EE showed, in addition to the expected 200 nm liposomal particles, 
larger particles of approximately 7000 nm. These particles accumulated, 
at least partially, with time at the top of the preparation as a lipid layer, 
and were assigned to non-encapsulated ω-3 PUFA-EE aggregates that 
piled in the top of suspension and could be easily removed from the 
preparation before further use. Smaller size goticules of approximately 
20-30 nm could also be detected by DLS, but disappeared with time, 
merging with others and migrating to the surface. The size of the 
liposomes loaded with Nanotex could not be measured with the DLS 
technique, since the nanoparticle demonstrated a high degree of 
reflectance incompatible with the size measurement. We investigated 
then the size of these preparations using TEM (Figure 3.2, bottom 
panels). Fig 2C-E show TEM images of empty liposomes, the nanoparticle 
Nanotex only and liposomes containing Nanotex, respectively. Empty 
liposomes (150-200 nm) required uranil acetate shadowing to become 
observable by TEM (2C), while Nanotex (7-8 nm diameter) was directly 
observable. Liposomes loaded with Nanotex (150-200 nm) showed also 
appreciable amounts of the superparamagnetic nanoparticle in the 
extraliposomal space. 
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3.3.2. Magnetic Resonance Spectroscopy 
A brief study of the characteristics of the ω-3 PUFA-EE used became 
necessary to elucidate the nature of its incorporation into the liposomes. 
To this end we investigated the properties of ω-3 PUFA-EE using 
Magnetic Resonance Spectroscopy. 
 
Figure 3.3. 1H HRMAS spectrum (500.13 MHz, 22 0C, 4000 Hz) of ω-3 
PUFA-EE in deuterated chloroform. Assignments in Table 3.1. 
Figure 3.3 shows representative 1H HRMAS spectra from a chloroform 
suspension of ω-3 PUFA-EE, acquired as indicated in Methods. The 
spectrum shows clearly resolved resonances from the magnetically 
different protons of the ω-3 PUFA-EE as specified in Table 3.1. It became 
possible to assign all observed resonances [103, 104]. 
Once the 1H HRMAS spectrum of ω-3 PUFA-EE was well characterized, it 
became possible to compare it with the spectrum of empty liposomes 
and liposomes containing ω-3 PUFA-EE. 
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Table 3.1.Assigments of ω-3 PUFA-EE resonances indicating the proton 
group and the corresponding chemical shift. 
 
Resonance Original protons ppma) 
1 -CH2-CH3 0.96 
2 CH3-CH2-OOC-R 1.25 
3 CH3-CH2-CH=CH-CH2- 1.69 
4 =CH-CH2-CH2-CH3 2.08 
5 =CH-CH2-CH3 2.30 
6 -OOC-CH2-  2.83 
7 -(CH2)p-(CH=CH)m-(CH2)n- 4.11 
8 -(CH2)p-(CH=CH)m-(CH2)n- 5.37 
9 Deuterated chloroform 7.28 
a) Chemical shifts refereed to the deuterated chloroform diluted in the sample. 
Figure 3.4 shows representative HRMAS spectra from liposomal 
suspensions containing (bottom) or not (top) ω-3 PUFA-EE. Note that the 
bilayer membrane structure of the liposomes precludes the observation 
of most resonances from the fatty acid chains. This is due to insufficient 
motional averaging in the NMR timescale because of the restrictions 
imposed by the bilayer structure of the membrane [105]. Interestingly, 
only resonances from the choline head group at 3.2 ppm and some 
methylene resonances from the fatty acyl chains (at 2.9 ppm) are 
sufficiently mobile to originate observable resonances in the empty 
liposomal preparation. Interestingly, resonances typical for the PUFA-EE 
(cf. Figure 3.3) can be easily distinguished in the preparation of liposomes 
containing fatty acids ester (bottom panel), revealing the incorporation 
of the fatty acid into the liposome, in a sufficiently mobile form to 
originate a high resolution NMR resonance. 
63 
 
 
Figure 3.4. 1H HRMAS (550.13 MHz, 4 0C, 4000 Hz) spectra liposomal 
preparations. Spectra of aqueous suspensions from empty liposomes (top) and 
from liposomes loaded with ω-3 PUFA-EE (bottom). Note that the spectrum of 
the liposomal suspensions loaded with ω-3 PUFA-EE is dominated by the 
resonances from the more mobile lipid droplets from ω-3 PUFA-EE. 
In particular, the methyl groups (resonance 1 of Table 3.1), the 
methylene group vicinal to the carboxylic group (resonance 7 of Table 
3.1) and the methyl groups corresponding to ω-3 PUFA-EE can be clearly 
resolved in the corresponding liposomal preparation. The observation of 
these resonances cannot be due to the incorporation of the fatty acid in 
the liposomal membrane, which would result in an almost complete 
immobilization of the molecule and disappearance of its high resolution 
NMR signals. Rather, these ω-3 PUFA-EE reveal the presence of 
sufficiently small fatty acid goticules in the liposomal preparation, able to 
originate high resolution signals through motional narrowing. This is 
confirmed by the DLS measurement (Fig. 3.2.b) which reveals the 
presence of sufficiently small PUFA-EE nanoparticles of approximately 30 
nm diameter. However, either the 1H HRMAS or DLS results do not reveal 
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if the ω-3 PUFA-EE goticules are present in the intraluminal space of the 
liposome, in the extraliposomal space of the suspension, or in both.  
To investigate this aspect we performed Diffusion Weighted 
Spectroscopy experiments (DOSY) [106]. This approach measures the 
Apparent Diffusion Coefficient of water (ADC) in the liposomal 
preparation. According to the Einstein´s principle the ADC is inversely 
proportional to the number of molecular obstructions that the water 
molecule would find along its random mean diffusional path [107]. The 
measurement of ADC is dominated by the contribution of the 
extraliposomal volume and if goticules would be present there at a 
significant proportion, one would expect a decrease in the observed ADC. 
In contrast, if goticules would be located inside the liposomes, no 
additional obstructions would be found in the extraliposomal volume and 
very similar ADC´s would be measured in the presence and absence of ω-
3 PUFA-EE. 
Figure 3.5 shows the results of DOSY measurements of water diffusion in 
liposomal suspensions containing or not PUFA-EE. No significant 
differences can be observed in the water ADCs values between both 
preparations at the three diffusion times, suggesting that the fatty acids 
ester droplets do not increase significantly the molecular obstructions to 
water movements. Since the ADCs are primarily dominated by those of 
the extraliposomal volume, present results suggest that most PUFA-EE 
goticules are localized in the intraluminal space or associated somehow 
to the membrane of the liposomal preparations. 
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Figure 3.5. 1H HRMAS DOSY (400,7 MHz, 22 0C) spectra of water 
diffusion in liposomal suspensions. Spectra were acquired in suspensions of 
liposomes loaded (top panels) or not (bottom panels) with ω-3 PUFA-EE, 
acquired with diffusion times of 100 ms (left), 50 ms (center) and 20 ms (right). 
Note that the presence of ω-3 PUFA-EE does not decrease significantly the water 
ADC, suggesting primarily an intraluminal location of the goticules. 
This could be demonstrated by the ultrafiltration experiments in which 
the goticules of -3 PUFA-EE suspensions passed easily and quite 
completely the 300 kD filters, while the suspensions of liposomes 
containing -3 PUFA-EE did not appreciably passed through filters of the 
same dimensions. This confirmed that -3 PUFA-EE goticules are 
predominantly intraliposomal as indicated by the water ADC 
measurements. 
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3.3.3. Magnetic Relaxation Properties of Liposomal 
Preparations 
We investigated the T1 and T2 magnetic relaxation properties of 
water molecules in suspensions of liposomes, containing or not 
Nanotex. Tables 3.2 and 3.3. summarize these results. 
Table 3.2. T1 values of different preparations (0.5mg Fe/mL, 0.25 mg 
Fe/mL and 0.125 mg Fe/mL) of liposomal suspensions containing or not 
Nanotex. 
 
Suspension type /       
concentration 
T1 (ms)a) 
0.5 mg/mL 0.25 mg/mL 0.125 mg/mL 
Liposomes without 
nanoparticles 2161.7 ± 154.6 2207.3 ± 107.9 2955.0 ± 7.1 
Liposomes whit 
nanoparticles 17.373 ± 0.006 34.17 ± 0.06 64.1 ± 0.1 
a) T1 values were determined at 1,5 Tesla (22
0C, Bruker Minispec, Rheinstetten, DE) using 
the inversion recovery sequence. 
 
Table 3.2 shows the values of T1 water relaxation time in liposome 
suspensions containing or not Nanotex in three successive dilutions of 
the maximal initial concentration. It can be observed that the T1 
relaxation value is shortest for the higher Nanotex concentration and 
increases approximately linearly when suspensions are diluted, giving a 
relaxivity value r1 of 6.26 mM-1·s-1. The same situation is observed with 
empty liposomes, albeit with a much slope for the increase in T1 
relaxation due to the absence of the superparamagnetic nanoparticle.  
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Table 3.3. T2 values of different preparations of liposomes with and 
without Nanotex (0.5mg/mL and solutions diluted to 50% and 25% of its 
initial concentration). 
 
Suspension type /        
concentration 
T2 (ms)a) 
0.5 mg/mL 0.25 mg/mL 0.125 mg/mL 
Magnetoliposomes 
without nanoparticles 1138.3 ± 34.6 1034.3 ± 6.1 2228.2 ± 0.14 
Magnetoliposomes whit 
nanoparticles 1.717 ± 0.006 3.48 ± 0.006 6.637 ± 0.015 
a) T2 values were determined at 1.5 Tesla (22 
0C, Bruker Minispec, Rheinstetten, DE) using 
the inversion recovery sequence. 
 
Table 3.3 shows T2 relaxation results of the different samples. T2 values 
for the original sample with Nanotex shows approximately 1000 times 
faster relaxation than the empty liposomes (Table 3.2). It can be 
observed that the T2 relaxation value is shortest for the highest Nanotex 
concentration and increases approximately linearly when suspensions 
are diluted, giving a relaxivity value r2 of 64.6 mM-1.s-1. The same 
situation is observed with empty liposomes, albeit with a much lower 
increase of T2 relaxation upon dilution. 
3.3.4. Fluorescence in vitro and in vivo 
The capacity of liposomes as optical biomarkers was tested using in vitro 
and in vivo fluorescence approach. Figure 3.6 summarizes the results 
obtained in vitro and in vivo with liposomes containing or not Nanotex, 
and labeled fluorescently with rhodamine-100. 
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Figure 3.6. Fluorescence imaging of liposomes. In vitro (A, B) and in vivo (C) 
fluorescence images of liposomes loaded with nanoparticles and rhodamine-100 
as acquired with the IVIS-Lumina camera. A: Visible picture of the 96 well plate 
used as phantom, showing the columns of wells loaded with decreasing (top to 
bottom) concentrations of empty liposomes (left column), liposomes loaded 
with rhodamine-100 (central column) and liposomes loaded with rhodamine-
100 and Nanotex (right column). B: Fluorescence image. Note the larger 
fluorescence of the liposomes containing rhodamine-100 only as compared to 
those containing rhodamine-100 and Nanotex. C: In vivo images reveal the 
presence of the liposomal preparations injected i.p., arrow left: liposomes 
containing rhodamine-100 and Nanotex, arrow right: empty liposomes. 
Figure 3.6A–B shows results obtained in the in vitro fluorescence 
experiment, comparing the fluorescence of empty liposomes (left track), 
liposomes containing rhodamine-100 (central track) and liposome 
containing rhodamine-100 and Nanotex (right track). Liposomes 
containing only rhodamine-100 present more fluorescence than 
liposomes containing both rhodamine-100 and nanoparticles. This may 
be due to either or both of two circumstances. First, liposomes with 
Nanotex have to share their lumen space with rhodamine-100 and one or 
more nanoparticles, resulting in a smaller intraluminal volume for 
rhodamine-100 accumulation and thus decreased rhodamine-100 
concentration. Second, Nanotex could partially quench the fluorescence 
of rhodamine-100.  
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Figure 3.6C shows the results of a representative in vivo experiment in a 
mouse receiving an i.p. injection of liposomes labeled with rhodamine-
100 containing (left side) or not (right side) Nanotex. As in the in vitro 
experiments, liposomes with Nanotex and rhodamine-100 depict less 
quantum efficiency than liposomes with only rhodamine-100, but they 
still become observable by in vivo fluorescence (Figure 3.6C). In this 
respect, the in vivo detection of magnetoliposomes with rhodamine-100 
in their lumen may open new ways in theragnostic methods using 
multimodal imaging detection combining MRI and fluorescence imaging.  
3.3.5. Anti-Inflammatory Effects in vivo in a Mouse Model of 
Colonic Inflammation 
We investigated the anti-inflammatory effects of liposomal preparations 
containing or not ω-3 PUFA-EE using a well-established model of colonic 
inflammation induced by dextran sulfate (sodium salt, DSS) 
administration. 
Figure 3.7 shows representative results of the administration of 
magnetoliposomes with and without ω-3 PUFA-EE in mice with rectal 
inflammation induced by DSS. Untreated mice (3.7A) or those treated 
with magnetoliposomes without ω-3 PUFA-EE (3.7B) showed clearly 
increased colonic wall thickness, easily observable in T1w images after 
Gd(III)DTPA enhancement. However, mice treated with 
magnetoliposomes containing ω-3 PUFA-EE (3.7C) depicted a significant 
reduction in colonic wall thickness, revealing an important anti-
inflammatory effect of the theragnostic preparation in the DSS model.  
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Figure 3.7. T1w MR Images of colonic inflammation in the rectal region 
of mice subjected to DSS administration for five days. A: untreated, B: 
treated with liposomes containing Nanotex and C: treated with liposomes 
loaded with Nanotex and ω-3 PUFA-EE. 
These results are summarized in Table 3.4. The therapeutic effects of ω-3 
PUFA-EE became even detectable in the DSS model by measuring the 
weight of the animals along the DSS treatment and several days later.  
Table 3.4. Rectal wall thickness of different groups treated 
with DSS. 
 
Condition Wall width (mm)a) 
PBS 0.69±0.13 
Magnetoliposomes without 
fatty acids SOLUTEX 0.43±0.17 
Magnetoliposomes with fatty 
acids SOLUTEX 0.27±0.05
b) 
a) The width of the rectal of CD1 mice was measured with ImageJ in T1w 
images obtained in a 7T magnet. 
b) p<0.05 
Notably, untreated mice or mice treated with magnetoliposomes without 
ω-3 PUFA-EE showed significant decreases in body weight, while mice 
treated with magnetoliposomes containing ω-3 PUFA-EE maintained 
their initial body weight along the treatment period, revealing a potent 
anti-inflammatory effect of the formulation. 
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We further investigated the effects of our liposomal preparations in the 
DSS model of colonic inflammation, using 18F FDG and PET-CT techniques. 
Figure 3.8 shows representative results of four different animal groups 
including a control without any treatment, an animal receiving a saline 
placebo treatment, and animals receiving magnetoliposomal 
preparations containing Nanotex with or without PUFA-EE. Colonic 18FDG 
uptake is observed in all animals. This uptake appears to be, however, 
higher in animals without liposomal treatment than in animals treated 
with magnetoliposomes either with or without PUFA-EE. 
 
Figure 3.8. PET-CT/FDG images of mice subjected to five days of DSS 
administration untreated (A), treated with placebo (B) or liposomal 
suspensions containing Nanotex (C) with or without ω-3 PUFA-EE (D). 
Increased 18F-FDG uptake may be associated to increased inflammation, 
because macrophages and neutrophils are known to consume large 
amounts of glucose or FDG. However, a statistical analysis failed to reveal 
significant differences between the different groups. This could be due to 
72 
 
the heterogeneous behavior of the colonic inflammation which affects 
different regions in the different animals making it difficult to compare 
the results of different subjects in the same region. Taken together, our 
results indicate that measurements of rectal wall thickness provide a 
more robust indicator to follow colonic inflammation and the effects of 
different therapies against colon inflammation. 
3.3.6. Anti-inflammatory Effects in vivo in a Glioma Mouse 
Model 
We then examined the effects of magnetoliposomes containing or not ω-
3 PUFA-EE in the inflammation associated to glioma growth, using the C6 
glioma models. 
 
Figure 3.9. Effect of magnetoliposomal preparations containing 
(bottom) or not (top) ω-3 PUFA-EE on the time course of glioma 
development after implantation of C6 cells in the mouse brain. Left 
panels (day 0), central panels (day 3), right panels (day 6). 
Figure 3.9 shows representative MRI T2w images of glioma evolution in a 
mouse treated with magnetoliposomes containing (bottom panels) or 
not (upper panels) ω-3 PUFA-EE. Mice receiving magnetoliposomes 
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without ω-3 PUFA-EE developed tumors to the same extent than controls 
receiving no treatment (not shown). However, mice receiving 
magnetoliposomes containing ω-3 PUFA-EE decreased notably the rate 
of glioma growth, and even increased the regression rate of the 
implanted glioma.  
Table 3.5. Assesment of tumor growth in mice receiving 
magnetoliposomes containing or not ω-3 PUFA-EE. 
 
Type of 
magneto 
liposomes 
administered 
Mouse Initial size (mm2)a) 
Final size 
(mm2) 
% increase (+red) 
or decrease (-blue) 
With ω-3 
PUFA-EE 
Mouse 1 12.624 2.825 -77.62% 
Mouse 2 6.07 0.396 -93.48% 
Mouse 3 8.952 0.347 -96.12% 
Mouse 4 24.377 10.179 -58.24% 
Without ω-3 
PUFA-EE 
Mouse 5 15.756 27.5 +74.54% 
Mouse 6 14.473 20.212 +39.65% 
Mouse 7 8.298 13.787 +66.15% 
 Mouse 8 12.72 18.87 +48.35 
None Mouse 9 38.89 131.82 +238.96 
a) Tumor area reflects the area including the tumor and surrounding inflammation as 
detected in coronal cross sections T1w images of acquired as indicated in Methods. 
 
In addition to the MRI results, it is important to comment in this model, 
the aspect and behavior of the mice. Mice with no treatment depicted 
74 
 
piloerection, decrease in motor activity and eventually hemiplegia and 
hemiparesis, becoming necessary to sacrifice them after two or three 
weeks to comply with bioethical criteria. However, mice treated with 
liposomes with fatty acids ester SOLUTEX did not present such 
symptoms, revealing significantly better physiopathological state and 
regression of the disease. Table 3.5 summarizes the results in an 
experiment including two different treatments, mice treated with 
magnetoliposomes containing or not ω-3 PUFA-EE, as well as control 
group with no treatment. The study of the T1 images revealed an intense 
anti-inflammatory effect in the mice treated with ω-3 PUFA-EE, inducing 
a reduction in the volume of glioma (and the edema) and eventually 
regression of the tumor. 
3.4. Discussion 
I have presented a novel liposomal formulation combining the 
therapeutic properties of -3 PUFA-EE with the non-invasive imaging 
capabilities of Nanotex or Rhodamine, or the combination of both. The 
preparation depicts potent anti-inflammatory effects against colonic 
inflammation and is endowed with spectacular and unexpected 
antitumoral effects against C6 glioma, providing a valuable illustration of 
a novel and successful theragnostic strategy 
Interestingly, the encapsulation of a superparamagnetic nanoparticle in a 
liposome results in different relaxivity properties as compared to those 
of the free nanoparticle in suspension. The relaxivity value r1 increases 
from 0.55 s-1 mM-1 for free Nanotex in suspension to 6.26 s-1 mM-1 for 
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Nanotex encapsulated in liposomes. In the case of r2, the value of 88.97  
s-1 mM-1 for free Nanotex in solution decreases to 64.61 mM-1 s-1 for 
encapsulated Nanotex. These changes reflect certainly modifications in 
the dynamics of the nanoparticle-water interaction induced by the 
encapsulation process. Indeed it would be expected that the 
encapsulation would decrease the interaction of the nanoparticle with 
the surrounding water, because of the insulating effects of the liposomal 
membrane barrier. These reduction effects are expected to occur mainly 
in the “outer sphere” relaxivity component, representing approximately 
50% of the total relaxivity [12, 108]. The “inner sphere” relaxivity 
component, reflecting mainly the direct interaction of the nanoparticle 
with water would be expected to be very similar in the free and 
encapsulated states, since it is determined by the magnetic properties of 
the nanoparticle and its size, two aspects that are not expected to 
change appreciably during the encapsulation process. The approximately 
30% decrease observed in r2 follows closely enough this interpretation. 
However, a similar decrease would also be expected to occur in r1. This is 
not observed, indicating that the “outer sphere” effect is not the only 
determinant of the changes in relaxivity occurring after liposomal 
encapsulation. The r1 value shows, in contrast, an important increase, 
larger than an order of magnitude. The most probable cause of this 
increase is a restriction in the rotational movement of the nanoparticle in 
the encapsulated environment. This may be imposed by, either an 
association to the liposomal membrane, an increase in intraluminal 
microviscosity, or binding or interaction with neighboring nanoparticles, 
resulting in a slower tumbling time ( r in [108]), reflected predominantly 
in r1. Indeed r1 and r2 have different determinants and behavior, as 
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explained from the different Solomon-Bloembergen-Morgan equations 
[108-111], and it is not surprising that they respond differently to 
encapsulation. Moreover, r1 and r2, reflect the different time scales of T1 
(s) and T2(ms), making easier to understand that the events occurring in 
the ms range of T2, may be too fast to be detected in the second range 
time-scale of T1. In conclusion, the encapsulation of Nanotex in liposomes 
appears to decrease the contribution of the “outer sphere” contribution, 
reflecting diffusional limitations imposed by the liposomal membrane, 
and decrease the tumbling time of the nanoparticle, revealing 
associations to the liposomal membrane or to other nanoparticles. 
The liposomal encapsulation -3 PUFA-EE merits also further comments 
[112, 113]. Our results show that it is possible to encapsulate significant 
amounts of the lipid soluble -3 PUFA-EE in the lumen of liposomes. This 
can be observed by the prominent 1H HRMAS resonances of liposomal 
suspensions containing the encapsulated fatty acids. The fact that these 
resonances are observed reveals that the -3 PUFA-EE are present as 
small, fast tumbling goticules inside the liposomes. This is because the 
similar -3 PUFA-EE goticules present in water suspensions, pass easily 
through 300 kD filters, while encapsulated -3 PUFA goticules, do not 
pass through the same filters, indicating that they are sequestered in the 
liposomal interior. This finding is further confirmed by the fact that 
liposomal preparations containing encapsulated -3 PUFA EE show the 
same ADC as the empty liposomal preparations, revealing that the 
obstructions contributed by the ω-3 PUFA-EE goticules do not contribute 
appreciably to the ADC of the suspension, dominated mainly by the 
extraliposomal compartment. 
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We have shown also that the magnetoliposomal preparations containing 
Nanotex and -3 PUFA-EE present important anti-inflammatory activity 
against colonic inflammation and spectacular antitumoral effects against 
glioma. 
Colonic inflammation is a disease associated to ulcerative colitis and 
Chron´s disease, two incurable pathologies at present. These are treated 
currently with conventional anti-inflammatory therapies [84], mostly free 
steroidal (budesonide) drugs, and eventually colonic resection by 
surgery. The formulation proposed here has been shown to become 
therapeutically useful in animal models of DSS intoxication, adding a 
new, non-toxic formulation to the arsenal of therapeutic methods 
against these two morbid and prevalent diseases. 
Finally, our liposomal formulation encapsulating -3 PUFA-EE and 
Nanotex has demonstrated spectacular effects against glioma, slowing 
down proliferation and even inducing remission.  These effects are due 
to the combination of Nanotex and the -3 PUFAA-EE since they are not 
induced by empty liposomes or liposomes containing -3 PUFA-EE only. 
The precise mechanism remains to be elucidated but could probably 
involve a decrease in the inflammatory component and cytokines 
required for glioma proliferation and invasion. 
In summary our results illustrate the properties and use of a new 
nanotechnological formulation including one or more imaging agents and 
a therapeutic molecule, useful in the treatment of the inflammatory 
component of colonic inflammation and glioma. A patent has been filed 
protecting the preparation, properties and use of this formulation [114].  
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Chapter 4 
Carbon Nanotubes as novel anisotropic 
contrast agents for MRI 
 
Chapter 4 provides a systematic study of the 
magnetic anisotropy properties of Carbon 
Nanotubes, their molecular determinants and 
their potential use in Magnetic Resonance 
Imaging studies of molecular orientation. 
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4.1. Introduction 
Carbon Nanotubes have reached considerable interest in Physics, 
Chemistry and Biomedicine because of their outstanding 
physicochemical properties including; electrical conductance, magnetic 
character, optical activity, thermal capacity, elasticity and chemical 
versatility [115-122]. These properties are thought to arise from their 
unique graphene structure as organized in a nanotubular arrangement, 
in which the asymmetric molecular organization determines the 
anisotropic physico-chemical properties [123-125]. The magnetic 
properties and their anisotropic behavior, entail particular interest in this 
respect, since amorphous graphite is known not to be magnetic, while 
carbon nanotubes are known to depict non zero magnetic moments, 
probably reflecting electron flow through -orbitals surrounding the 
hexagonal or pentagonal ring constituents [126, 127]. Indeed, a number 
of studies have addressed the magnetic properties of carbon nanotubes, 
either theoretically [119, 125-129] or experimentally [130-133]. 
The use of carbon nanotubes as anisotropic contrast agents in Magnetic 
Resonance Imaging entails particular relevance, since virtually all 
currently available contrast agents depict an isotropic behavior. Indeed 
the use of an anisotropic contrast agent would allow to obtain the three 
dimensional spatial orientation of molecular assemblies to which it binds, 
including potentially receptors, microvascular perfusion arrangements 
and specific cellular populations, in a very similar manner to that 
afforded by the Diffusion Tensor Imaging with anisotropic water diffusion 
[134, 135]. However, the origin of their magnetism, their precise 
magnetic properties and their dependence on molecular orientation in 
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suspensions of carbon nanotubes, remain still poorly characterized. To 
progress in this respect, we investigated here the magnetic and optical 
anisotropies of Single Walled Carbon Nanotubes (SWCNTs) and Multi 
Walled Carbon Nanotubes (MWCNTs), assessing the possibilities to use 
these preparations as advanced anisotropic contrast agents in 
multimodal imaging and particularly in MRI. 
4.2. Materials and methods 
4.2.1. Single Wall Carbon Nanotubes 
Preparation 
Three different samples of Single Walled Carbon Nanotubes (SWCNTs) 
were investigated. Starting from commercial SWCNTs (Sigma-Aldrich, 40-
60%, prepared by chemical vapour deposition, CVD) with initial 
diameters of 2-10nm and lengths of 1-5μm, contaminated with residual 
Ni (17%) and Y (4%) catalysts, we prepared samples of SWCNTs oxidized 
for increasing times of 24 and 48h [136]. The original sample (200 mg) 
was suspended in HNO3 (65%, 25 ml) and heated to 100 0C under reflux 
during either 24 or 48 h [137]. The reaction mixture was cooled down 
and diluted with deionized water (100 ml). The resulting suspension was 
centrifuged at 3000 rpm for 10 min and the precipitate was resuspended 
in deionized water, placed inside a dialysis membrane (Spectra/Por® 3 
Dialysis Membrane, MWCO 3500 Da, SpectrumLabs, Rancho Dominguez 
CA, USA) and dialyzed against water until pH 5.5. The dialyzed suspension 
was centrifuged to isolate the SWCNTs which were then dried by rotary 
evaporation.   
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Characterization 
Water soluble SWCNTs were characterized using atomic force 
microscopy (AFM), high resolution transmission electron microscopy with 
energy dispersive spectrometry (HRTEM-EDAX), thermogravimetric 
analysis (TGA) and X-Ray fluorescence (XRF). 
AFM Microscopy 
The Atomic Force Microscopy (AFM) images were obtained with a 
commercial AFM (Nanotec Electronica, Cervantes FullMode AFM System, 
Tres Cantos, Madrid, ES) and monocrystalline silicon cantilevers 
(Nanosensors PointProbe Plus, Neuchatel, SW) of force constant 2.8 N/m 
and resonance frequency 75 kHz,. The nanotubes were dispersed in 
water by ultrasonic agitation (ultrasound bath, 15 min) at a 
concentration of about 1 mg/ml. The supernatant (2μL) were deposited 
onto a cleaved muscovite mica substrate and let air-dry for subsequent 
AFM observation.  
HRTEM with EDAX 
High Resolution Transmission Electron Microscopy (200 and 400 kV, 
JEOL, JEM-2000 FX and JEM-4000 EX, Alcobendas, Madrid, ES) in 
combination with Energy Dispersive X-Ray Analysis (EDAX) was used to 
determine the metal composition of the contaminant nanogranules. For 
this study, a few drops of an aqueous and methanol dispersion of the 
material were placed on a copper grid and evaporated prior to 
observation.  
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Termogravimetric Analyses (TGA) 
We used TGA to assess the effect of the oxidation time on the total 
amount of metal catalyst present. Thermogravimetric analyses were 
performed on a thermobalance TGA Q500 (TA Instruments, Barcelona, 
ES) using the following conditions. Nitrogen atmosphere: Temperature 
ramp-rate: 50 °C/min, heating: 20-900 °C. Air atmosphere: Flow rate of 
90 ml/min, Temperature ramp-rate of 50 °C/min, heating from 20 to 
1000 °C. 
X Ray Total Reflection Fluorescence (TXRF) 
TXRF spectra were acquired with a TXRF Extra-II (Rich&Seifert, DE) 
spectrometer. 
Superconducting Quantum Interference Device (SQUID) 
To measure the hysteresis loops by SQUID we used the different SWNTs 
samples (commercial, 24h and 48h) dissolved in Fetal Bovine Serum 
(2mg/ml) and ultrasonicated 15 minutes. The sample was put inside de 
SQUID magnetometer (Quantum Design MPMS XL-5, San Diego, 
California, USA) in a liquid state. We applied a 5T field to orientate the 
nanotubes and then frozen the sample to maintain orientation. We 
measured the hysteresis loop at 5K in two directions, in the parallel and 
perpendicular axes of the nanotube with respect to the external 
magnetic field.  
Magnetic Resonance Imaging (MRI) 
For the Magnetic Resonance Imaging measurements, we mixed the 
SWCNTs suspension with melted agarose (0.5%, low melting 370C, 
Sigma-Aldrich, St. Louis, Mo, USA), and cooled down (220C) to form a 
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solid gel inside a 7T magnet. This protocol was able to maintain oriented 
the SWCNTs in the B0 direction while gelling, keeping thereafter this 
orientation in the solid agarose matrix. The SWCNTs oriented sample was 
placed in an Eppendorf tube accommodated to a home-made 
goniometer, allowing the manual rotation of the sample inside the 
magnet (Figure 4.1).  
 
Figure 4.1. Home-made goniometer for directional MRI measurements. 
This device makes it possible to rotate the sample in multiple directions inside 
the magnet, including the parallel and perpendicular orientations to the 
magnetic field. 
We measured T2 values varying the orientation of the sample with 
respect to B0. We used a  spin echo sequences (TR=5000ms, TE=12ms) as 
implemented in a Bruker Pharmascan 7 Tesla scanner (Bruker Daltonics, 
Ettlingen, DE), employing a 38 mm volume coil. The Magnetic Resonance 
Imaging measurements were analysed pixel by pixel with the home made 
MyMap Analyzer software based in MatLab (MathWorks, Natick, 
Massachusetts, USA) to obtain the corresponding T2 map. 
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Cytotoxicity 
We investigated cellular toxicity of SWCNTs oxidized for 24h using two 
different methods, either assessing mitochondrial function (MTT assay) 
or plasma membrane integrity (LDH assay), respectively. C6 cells were 
grown to confluence in Dulbecco's Modified Eagle Medium (DMEM) 
using 96 well plates. SWCNTs suspensions prepared on Fetal Bovine 
Serum (FBS) (Gibco, Life Technologies, Alcobendas, Madrid, ES), were 
added to each well in final concentrations of 1, 10, 100 and 1000 μg mL-1, 
using three cell replicas for every SWCNTs concentration. The viability of 
the cellular preparations was determined spectrophotometrically 
(570nm, Spectramax, Molecular Devices, Downington, PA, USA) 1h and 
24h after the addition of the different SWCNTs suspensions, using 
commercial kits to determine mitochondrial performance as the 
reduction of tetrazolium salts (MTT, Millipore, Billerica, MA, USA). As 
blank we used the medium from cells incubated in the absence of 
SWCNTs while cell death was induced by adding the toxic hydrazine (5 
mM) to the incubation medium. 
4.2.2. Multiwall Carbon Nanotubes  
Preparation 
We used commercial Multi-Walled Carbon Nanotubes (MWNTs < 10 nm 
outer diameter, 1-2 μm length) synthesized by chemical vapor deposition 
(CVD) (SES Research Houston TX USA).  To prepare the nanotube treated 
samples, the first step was the fragmentation of MWCNTs consisting in 
an oxidation under sulfonitric conditions during 24 hours in an ultrasonic 
bath at room temperature. This step is necessary to obtain shorter 
carbon nanotubes that were subsequently derivatized by π-π stacking 
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forming adducts with aminopyrene, which are significantly more soluble 
than the commercial and oxidized MWCNTs. Pristine MWCNTs (330 mg) 
were sonicated in a water bath for 24 h in 48 mL of sulfuric acid / nitric 
acid (3:1 v/v, 98% and 65% respectively) at room temperature [138-140]. 
The preparation followed then a sequence of rehydration with deionized 
water and filtration (0.45 μm, Omnipore membrane filtration, Millipore, 
US) until pH became neutral. Finally the sample was dried, obtaining an 
84% of nanotubes oxidized (MWNTsCOOH). To stack the aminopyrene 
adduct, 25 mg of MWCNTsCOOH were suspended in 65 mL of DMF, 
ultrasonicating the suspension  at 25 0C during 48 hours [141].  
After that, when the suspension appeared homogenous, 160 mg of 
aminopyrene were added and then the mixture was stirred 3 hours. The 
π-π stacking adducts formation was confirmed by TLC (Thin Layer 
Cromatography). The residue was washed with Et2O and filtered (0.45 
μm, Omnipore membrane filtration, Millipore, US). 
Characterization 
The samples of MWCNTs (commercial, oxidized and oxidized containing 
aminopirene) were characterized by Transmission Electron Microscopy 
(TEM). Transmission Electron Microscopy experiments were performed 
using JEOL JEM 2100 microscope (JEOL Ltd., Tokyo, JAP) operating at 200 
kV. For TEM visualization, samples were prepared by dropping a solution 
of the compounds on a carbon copper grid (300 mesh). 
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Figure 4.2. Experimental set-up of the magnetic aligment experiment 
detected with the fluorimeter. Scheme A: Light produced in a Xe Lamp goes 
through a monocromator to illuminate the sample at 510 nm, the same 
wavelength detected. Before and after the sample path, there are two polarizing 
lenses used to measure the anisotropy. An electromagnet allows to apply 
magnetic field transiently or continuously. B: Photograph of the device. 
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Magnetooptical studies of nanotube alignment 
Light Dispersion 
To investigate the alignment of the nanotubes in suspension (N,N 
dimethyilformamide, DMF, 3mg/mL) we used a QuantaMaster 
fluorimeter (PTI, Birmingham, NJ, USA) allowing for the measurements of 
light dispersion and anisotropy in the samples.  
For the magnetic alignment of the preparations we used a home-made 
arrangement placed inside the fluorimeter, consisting of an 
electromagnet with its poles applied to the top and bottom of the 
fluorescence cuvette, leaving free the optical path. The field intensity of 
this magnet is 50 Gauss (5·10-3 T). The experimental set-up is shown in 
Figure 4.2. 
Light Absorption 
The orientation of the nanotubes was further investigated by following 
spectrophotometrically (LAMDA 1050 UV/Vis/NIR, PerkinElmer, 
Waltham, MA, USA) the changes in absorbance with sample orientation 
in the nanotube suspensions. Two types of MWCNTs samples were used, 
either MWCNTs in solution (Dimethylformamide, DMF, 3 mg/mL) or 
MWCNTs magnetically oriented and fixed in a solid block of agarose 
(Sigma-Aldrich, St. Louis, Missouri, USA, 0.5%). In the solution study we 
used the same home-made magnet described in the light dispersion 
studies (Figure 4.2.B). 
For the study in the solid block of agarose, MWCNTs were dissolved in at 
high temperature (60 0C) in liquid agarose and accommodated overnight 
inside a 7T Bruker Pharmascan magnet (16 cm bore) to orient the 
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nanotubes while liquid and keep them  fixed along Bo direction while 
gelling. This experimental set-up is described in Figure 4.3.  
 
Figure 4.3. Experimental set-up of magnetic aligment detected through 
the absorption of polarized light. Light produced by an halogen lamp passes 
through a monochromator to illuminate the sample at 340 nm. A polarizing lens 
is located between the monochromator and the sample to allow rotation of the 
polarizing plane of light. 
Magnetic Resonance Imaging 
MRI techniques were used in the study of the alignment of the carbon 
nanotubes. T2 maps were obtained from a solid block of agarose with 
nanotubes fixed in a known direction. The sample was manually rotated 
inside a 7T Bruker Pharmascan and T2 maps (spin-echo sequence, 
TR=5000 ms, TE=12 ms) were acquired in two orthogonal directions, 
parallel and perpendicular (Figure 4.1). The T2 maps were analysed using 
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MyMap Analizer, an in a home written software for image analysis based 
in MatLab libraries. 
4.3. Results 
4.3.1. Determinants of Magnetic Anisotropy in SWCNTs 
Suspensions 
Oxidation of the nanotubes modifies their length as detected by Atomic 
Force Microscopy (AFM). Figure 4.4 shows representative Atomic Force 
Microscopy (AFM) images of either commercial preparations of SWCNTs 
(Figure 4.4 A) or those obtained after nitric acid treatment for 24h 
(Figure 4.4 B) or 48h (Figure 4.4 C). These panels illustrate the classical 
nanotubular structures containing characteristic metal catalyst granules 
as detected with AFM [136]. The nitric acid oxidation treatment (24h-
48h), reduced notably the SWCNTs length from 1-5 μm in the commercial 
preparation to 200-700 nm in the 48h oxidized preparation, reducing also 
the number of observable metallic granules. The oxidation process 
increased concomitantly the width of the shortened tubes, roughly from 
1 nm in the commercial preparations to approximately 5-15 nm after 24h 
or 48h oxidation (Figure 4.4 D). Reduction in length is derived from 
oxidative breakdown of the nanofilaments while the increase in diameter 
may be caused by the longitudinal folding and stacking of two or more 
nanotube fragments, containing or not some residual Ni covering.  
Thermogravimetric analysis (TGA) showed a decrease in the total metal 
content from 33% in the commercial preparations of SWCNTs to 20% and 
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8% in the preparations oxidized for 24 or 48h, respectively (Figure 4.4 E) 
[137]. 
 
Figure 4.4. Characterization of Single Walled Carbon Nanotubes. 
Representative AFM images of SWCNTs preparations before (A) and after 
oxidation during 24 (B) and 48 h (C). The metal granules of the samples are easily 
observed. Height-Length plots obtained by AFM during shortening of SWCNTs 
before and after oxidation during 24 and 48 hours (D). Nanotubes become 
shorter upon oxidation and their height increases. TGA analysis shows a 
decrease in the content of metal contaminants with the oxidation time of the 
SWCNTs preparations (E). Metal content decreases with oxidation time. HRTEM 
with EDAX microanalysis shows that the catalytic nanoparticle is composed of Ni 
(insert) and Y (F). The peaks of Carbon, C, and Copper, Cu, correspond to 
SWCNTs and the grid, respectively. 
To investigate the metal composition in the preparations we 
implemented High Resolution Transmission Electron Microscopy with 
Energy Dispersive X-Ray Analysis (HRTEM-EDAX), as indicated in the 
Materials and Methods section. Figure 4.4 F shows the results obtained 
which revealed Ni and Y as the principal paramagnetic metal 
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contaminants of the metallic nanogranules (Figure 4.4 F, insert), the Cu 
signals being derived mainly from the grid [137]. Roughly, Ni and Y 
content of the commercial preparations (17.6 % and 4.3 %), decreased 
after 24h oxidation (5.1 % and 0.9%) and even further after 48h oxidation 
(3.3 % and 0.6 %), as detected by Total X Ray Fluorescence Reflection 
spectrometry (TXRF) respectively [136]. 
We next explored, the magnetic properties of the SWCNTs preparations 
oxidized for increasing times using SQUID (Figure 4.5). 
 
Figure 4.5. Magnetic properties of SWCNTs. Magnetic hysteresis Loops (full 
dots, continuous lines) and virgin curves (empty dots, dotted lines) of SWCNT 
preparations oxidized with nitric acid for 0h (A), 24h (B) and 48h (C). Evolution of 
magnetic anisotropy along chemical treatment time (D). Note the increase in the 
magnetic anisotropy value with increasing oxidation time. 
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To measure hysteresis loops and virgin curves by SQUID we used the 
SWCNTs samples (commercial, 24h and 48h) dissolved in Fetal Bovine 
Serum (2mg/ml) and ultrasonicated 15 minutes. Magnetic hysteresis 
loops were measured at 5 K and angles of  = 0 degrees and  = 90 
degrees, with respect to the direction of the applied magnetic field, for 
oriented nanotube suspensions. Briefly, the nanotube suspensions were 
introduced in the magnet in the liquid state for orientation, and frozen to 
5K where they remained oriented and fixed within the ice matrix. We 
measured then, virgin curves and hysteresis loops under these conditions 
and after 90 degrees rotation of the frozen sample. These measurements 
revealed clearly a paramagnetic behavior [142]. When the commercial 
SWCNTs preparation was oriented parallel to the external magnetic field 
(blue circles and lines), the magnetizations detected were larger than 
those measured in the perpendicular direction (red circles and red lines) 
(Figure 4.5 A). The same behavior was observed in SWCNTs preparations 
oxidized for 24h (Figure 4.5 B) and 48h (Figure 4.5 C), although the 
magnitudes of total magnetization and magnetic susceptibility were 
different in each case. In addition, the virgin curves (empty circles) 
revealed that magnetic susceptibility of SWCNTs is larger when measured 
in the parallel than in the perpendicular orientations. Notably the 
magnitude of the magnetic anisotropy ( ) 
increased from 0.14 in the commercial preparation, to 0.26 and 0.35 
after 24h and 48h oxidation, respectively (Figure 4.5 D).  
Considering that the 24 and 48h nitric acid oxidations decrease the 
length, increase the diameter and decrease the metal content (Figure 4.4 
D and E), these results suggest that the increase in magnetic anisotropy 
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of the SWCNTs preparations (Figure 4.5) is caused by the changes in 
these properties. Increased magnetic anisotropy of SWCNTs preparations 
oxidized for 24 or 48h, may thus reflect an easier alignment in the 
magnetic field of the shorter nanotubes than of the commercial 
nanofilaments, including also the formation of longitudinal aggregates 
with larger diameter (c.f. Figure 4.4 D).  
We further investigated then the determinants of magnetic anisotropy in 
SWCNTs preparations using Magnetic Resonance Imaging. We prepared 
first an oriented sample of commercial SWCNTs in solid agarose (0.5% 
w/v) by suspending the SWCNTs in melted agarose (60 0C) and allowing 
the mixture to cool down to room temperature until the agarose became 
a solid gel, entrapping the SWCNTs [136]. We investigated then the 
anisotropy contributed by soluble Ni ions and by superparamagnetic Ni 
nanoparticles in the SWCNT suspension. To achieve this, we begun by 
entrapping a 10 mM NiCl solution (Sigma Aldrich, Alcobendas, Madrid, 
ES) in solid agarose (0.5% w/v). We entrapped also in agarose 
suspensions commercially available Nickel nanoparticles (577995, Sigma 
Aldrich, MO, USA).  
Note that a significant difference of average T2 values is observed in the 
SWCNTs gel between the two orthogonal orientations, while no 
difference is detected in the gels with NiCl2 or Ni nanoparticles. 
We obtained then MR images at room temperature, weighted in the 
transversal relaxation time (T2w), of the SWCNTs preparations (Figure 4.9 
upper left panels), of the Ni gel (Figure 4.9, middle left panels) and of the 
superparamagnetic nanoparticles gel (Figure 4.9, lower left panels) in the 
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parallel and perpendicular directions to the external magnetic field using 
a home-made goniometer (Figure 4.1).  
 
Figure 4.6. T2 imaging of SWCNTs suspensions oriented in agarose gels 
at room temperature (22 0C). Water T2 maps (left panels) for Single Walled 
Carbon Nanotube preparations (top), a NiCl2 solution (center) and 
superparamagnetic nanoparticles (bottom), as embedded in solid agarose gels 
(0.5%) oriented parallel || or perpendicular  to the static magnetic field B0. 
Average T2 values for the three preparations (right panels).  
T2 maps were then calculated pixel by pixel from the collection of images 
as indicated in Supplementary Information. The bargraphs (Figure 4.9, 
right panels) summarize the average T2 values of the pixels from SWCNTs 
(upper right panel), oriented Ni gels (middle right panel) and oriented Ni 
nanoparticle gels (lower right panel), when the solid agarose gel was 
oriented parallel (blue) or perpendicular (red) to the static magnetic field. 
As control we obtained the same T2 maps from agarose gels devoid of 
SWCNTs, Ni ions or Ni nanoparticles. 
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Note that the SWCNTs preparations depict significantly larger T2 water 
values when oriented in the parallel (blue) than in the perpendicular 
(red) directions, as revealed by the shift to the green in Figure 4.9 (upper 
left panels) and the values shown in the corresponding bar graphs (right 
panels). Notably, the pure agarose gel, and the Ni ion and Ni nanoparticle 
gels showed the same T2 values in the parallel and in the perpendicular 
directions. Taken together, these observations indicate that soluble Ni 
ions, spherical superparamagnetic nanoparticle suspensions or the 
agarose gel itself, do not present an intrinsic anisotropic behavior.  
4.3.2. SWNCNTs Cytotoxicity 
For its potential use as a contrast agent in MRI, it was necessary to 
measure the toxicity of SWCNTs (Figure 4.11). We observed 
approximately 100 % cell viability in the absence of SWCNTs and roughly 
null viability in cells exposed to the toxic. A decrease in formazan 
production was detected at the highest SWCNTs concentrations, a 
finding that has been described previously to be due to a direct reaction 
of the nanotubes with the MTT molecule, rather to a cytotoxic effect on 
the cells [143]. To further investigate cytotoxicity, we performed 
additional tests using the same SWCNTs preparation but measuring the 
release of lactate dehydrogenase (LDH) from the cell suspensions as an 
indicator of plasma membrane integrity and cell viability (Figure 4.11, B, 
D). 
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Figure 4.7. Study of citotoxicity of SWCNTs. MTT assays (A,C) and fractional 
LDH release assays (B, D) of cellular viability for increasing concentrations of 
SWCNTs oxidized with nitric acid for 24h, either 1h (A, B) or 24h (C, D) after the 
addition of the SWCNTs suspensions (1-1000 μg mL-1) in Fetal Bovine Serum to 
the cells. 
Briefly, SWCNTs were added to each well to final concentrations in the 1-
1000 μg.mL-1 range. LDH activity was determined spectrophotometrically 
(340 nm, Spectramax, Molecular Devices, Downington, PA, USA) 
following the linear decrease in NADH absorbance in mixtures containing 
50 mM HEPES pH: 7.0, 5 mM pyruvate and 0.6 mM NADH. We initiated 
the reaction with the addition of either aliquots from the incubation 
medium or from the cell lysate obtained after four cycles of freezing and 
thawing. We used as blanks, aliquots of the incubation medium 
containing no SWCNTs and as a maximum LDH release, that induced by 
adding the detergent sodium dodecylsulfate (2%) to the cell suspensions. 
We determined then the fractional LDH released (LDH medium/(LDH 
medium+LDH lysate) either after 1h or 24h incubations. While we 
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observed no significant fractional LDH release in the blanks or close to 90 
% after detergent treatment as expected, we detected no significant 
increase in fractional LDH release with increasing concentrations of 
SWCNTs either after 1h or 24h incubations. Taken together, our results 
revealed no significant cytotoxic effects of our SWCNTs preparations in 
the concentrations required for observable magnetic anisotropy effects. 
4.3.3. Characterization of Different Preparations of 
MWCNTs 
We began by characterizing the MWCNTs preparation using Transmission 
Electron microcopy (TEM). Figure 4.8 shows representative results of 
commercial preparations and those obtained after the shortening 
treatment. The commercial sample shows important heterogeneity with 
the presence of abundant impurities and random bundles of 
nanofilaments (Figure 4.8 A and B). 
It became then necessary to shorten them by oxidation and sonication to 
obtain a more homogenous sample prior to further studies. After the 
oxidation treatment, the bundles began to disentangle and the shorter 
nanotubes generated become freer, with some aggregates produced by 
electrostatic forces still present (Figure 4.8 C and D). 
Adsorption of aminopyrene to the nanotubes resulted in a more 
homogenous sample with fewer nanotubes forming bundles (Figure 4.8 E 
and F). We obtained a histogram of the treated sample to determine a 
median value for the length of oxidized MWCNTs with aminopyrene in 
this preparation (Figure 4.9). 
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Figure 4.8. TEM images of MWCNTs preparations. Top panels: Commercial 
nanotubes form abundant bundles as shown at different magnifications (A: 6k, 
B: 30k). Central panels: Oxidized MWCNTs show some free nanotubes but also 
abundant nanotube bundles at different magnifications (C: 15k, D: 50k). Bottom 
panels: Treatment of oxidized MWCNTs with aminopyrene reveals that almost 
every bundle has been broken to free nanotubes at different magnifications (E: 
6k, F: 30k ). 
The histogram showed an average length of 170 nm for the most 
populated group. These results show that the nanotubes oxidized and 
with amynopirene bound, constitute a homogenous dispersion which can 
be suspended in water for further magneto-optical experiments. 
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Figure 4.9. Histogram of MWCNTs length after treatment. The most 
populated size is around 170nm. 
4.3.4. Magneto-Optical Evidences of MWCTs Alignment with 
External Magnetic Fields 
We investigated magnetic alignment and anisotropy using these 
preparations. To this end, it was necessary first, to confirm that our 
MWCNTs present sufficient magnetism and are able to orient in a 
magnetic field at room temperature. A light dispersion experiment was 
designed to investigate the magnetic behavior of MWCNTs. A stable 
solution of nanotubes suspended in dimethylformamide (DMF) was 
placed inside a fluorimeter which permited us to collect the dispersed 
light of the sample at a perpendicular direction to the illumination 
direction, using crossed polarizers (see Figure 4.2 for the experimental 
set-up). We prepared an electromagnet with poles on the top and 
bottom of the quartz cuvette, able to induce a transient or continuous 
magnetic field through the nanotube suspension, while leaving 
unperturbed the optical path. We made then successive light dispersion 
measurements in which the photons dispersed by the sample were 
collected successively in the detector with the magnetic field turned “on” 
or “off” (Figure 4.10). We observed that the presence of the magnetic 
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field induced significant increases in the dispersion while present, 
revealing magnetic field orientation of the MWCNTs sample. 
 
Figure 4.10. Photon counts of dispersed light collected successively in 
the fluorimeter when switching the magnetic field “on” or “off”. The 
number of counts detected is higher when the magnetic field is switched “on” 
and decreases if the magnet field is switched “off”, in a reproducible manner. 
We did one further experiment by switching “on” continuously the 
magnetic field. In this case, the collected counts increased with time, 
suggesting that the nanotube orientation of the sample is not 
instantaneous and that the number of nanotubes oriented parallel to the 
magnetic field may increase progressively with the time of exposure 
(Figure 4.11). 
When the magnetic field was switched on the number of counts 
recollected increased linearly with time, suggesting a reorganization of 
the nanotubes suspended in the sample parallel to the magnetic field so 
that the photons dispersed more light in the direction of the detector. 
(Figure 4.12). 
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Figure 4.11. Photon counts collected in the fluorimeter with time while 
switching the magnetic field “on” or “off” continuously. With the 
magnetic field turned “on” from the beginning, the number of counts detected 
increases linearly with time. 
 
Figure 4.12. Light dispersion in the fluorimeter. With the field “on” the 
nanotubes reorient parallel to the magnetic field dispersing more photons to the 
detector than when the field is off. 
Anisotropy measurements were also done with the fluorimeter using 
polarized light. For this experiment two polarizers were accommodated 
at the exit of the Xe Lamp and in the center of the detector. The 
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orientations of the polarizers were automatically set by the fluorimeter 
controls. The fluorimeter calculates the anisotropy of a sample by 
illuminating the sample with light polarized vertically and horizontally 
and analyzing the intensity of the light in the detector. The anisotropy is 
calculated using the equation: 
 Eq. 4.1 
where IVV is the intensity of the light when both polarizers were in 
vertical position, IVH with the lamp polarizer vertically and the detector 
polarizer horizontally and G is the G-factor is just a correction for the 
polarization given by 
 Eq. 4.2 
where IVH is the intensity of the light when the lamp polarizer is oriented 
horizontally and the detector polarizer is vertically and IHH when both are 
horizontally. 
The anisotropy was measured along time in two different conditions, 
with the magnetic field switched “on” and switched “off” (Figure 4.13). 
When the magnetic field is switch “on” the sample becomes more 
anisotropic, suggesting that the nanotubes orient parallel to the 
magnetic field reaching an anisotropic structure. 
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Figure 4.13. Light dispersion anisotropy values along time in the 
presence and absence of external magnetic field. Note that the nanotube 
sample becomes more anisotropic with the magnet field switch on. 
A similar experiment was performed using spectrophotometric detection 
with the nanotube suspension containing bound aminopyrene in DMF 
(Figure 4.3). First of all, we measured the absorption spectra of the 
sample, finding a maximum at 340 nm, corresponding to the 
aminopyrene ring [144]. The sample was then illuminated with polarized 
light (340 nm). When the magnet field was switched “on” and the 
nanotubes were perpendicular to the polarized light, the absorbance of 
the sample increased until the magnet field was switched “off” (Figure 
4.14). 
The next step was to fix the MWCNTs with a known direction in a matrix 
which permits us to measure the sample in two different directions in 
MRI. An agarose gel was chosen again for this purpose, keeping it inside a 
7 Tesla magnet to fix the nanotubes parallel to the magnetic field 
direction. To prove that the nanotubes were fixed in that direction we 
made measurements using the same spectrophotometric set up used to 
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study the nanotubes suspension. In this experiment we accommodated 
the matrix gel with nanotubes fixed in a known direction and the 
polarized light was rotated 3600 (Figure 4.15).  
 
 
Figure 4.14. Absorbance (340 nm) vs time curve of MWCNTs suspension 
in DMF, in the presence (ON) and absence (OFF) of magnetic field 
orientation. The absorbance increased when the magnet field was switched 
on. 
The transmittance of light was maximum when the polarization of the 
light was perpendicular to the nanotubes (Figure 4.15 A). The 
transmittance reaches a minimum when the light is parallel (around 900) 
and goes to maximum after a rotation of 1800. When the sample was 
rotated 900 we obtained a specular figure (Figure 4.15 B). This is due to 
the -  absorption of the aminopyrene molecule over the nanotube wall 
which results in different absorption properties depending on the 
orientation of the molecule [144]. The aminopyrene is coupled to the 
nanotube with its 340 nm absorption axis parallel to the nanotube[145]. 
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These results reveal that when the nanotube is parallel to the light 
polarization plane the absorption is maximum.  
 
 
Figure 4.15. Transmittance of a fixed MWCNTs suspension in a solid 
agarose support for different orientations of the light polarization 
plane. A: MWCNTs fixed agarose gels are oriented perpendicular to the initial 
polarization plane (0 degrees). The transmittance reaches maximum values 
(minimal absorption) when the polarization plane is perpendicular to the longest 
nanotube axis. B: MWCNTs fixed agarose gels are oriented parallel to the initial 
polarization plane (0 degrees). The transmittance reaches minimal values 
(maximal absorption) when the polarization plane is parallel to the longest 
nanotube axis. The noise in A and B is different because of the different 
orientation and inclination of the agarose gel during the spectrophotometric 
measurement.  
4.3.5. Magnetic Measurements of Relaxation Times for 
Oriented MWCNTs 
Magnetic anisotropies have been also studied using the solid agarose 
model to fix the nanotubes. It was measured the transversal relaxivity 
(T2) of MWCNTs with MRI techniques. T2 maps of a solid gel of agarose 
with nanotubes oriented were measured in two different directions, 
parallel and perpendicular to the magnetic field (Figure 4.16). 
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In summary, our magneto-optical measurements confirm that MWCNTs 
suspensions align with external magnetic fields at room temperature. 
 
Figure 4.16. T2 values of MWCNTs fixed in agarose at different 
directions. Significant differences (p<0.05) of T2 values of MWCNTs fixed 
in agarose in two different directions. 
We obtained similar results than the experiments with SWCNTs, with 
significant differences between the two measurements of the sample, 
parallel and perpendicular to the magnetic field. 
4.4. Discussion 
Using SWCNTs or MWCNTs preparations, I have shown that magnetic 
and optical anisotropy are macromolecular properties which are 
conserved in these materials even at room temperature. In this sense, 
magnetopoptical anisotropy of SWCNTs and MWCNTs add to the large 
collection of outstanding properties of carbon nanotubes as electrical 
conductance, thermal capacity or elasticity [115-122]. This is particularly 
relevant in the MRI contrast agent field since the most widely used 
gadolinium chelates and superparamagnetic nanoparticles depict 
isotropic magnetic relaxation properties. Indeed the free energy barriers 
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for molecular reorientation are very low for subnanometric structures as 
the gadolinium chelates, or even for spherical nanoparticles and 
thermally driven molecular reorientation averages the magnetic moment 
in isotropic manner, at room temperature [146]. The behaviour of 
tubular nanometric structures is different and the energy barriers 
required for thermal reorientation at room temperature are sufficiently 
large to preclude nanotube reorientation at room temperature, thus 
providing the thermodynamic basis for alignment phenomenon. We 
believe this is an outstanding finding since it may allow the non-invasive 
determination of the three dimensional orientation of the nanotube 
from magnetic resonance measurements of the relaxation properties of 
the surrounding water in different directions or the diffusional behaviour 
of water as obtained from Diffusion Tensor Imaging [135]. This would 
potentially allow to unravel non-invasively and in vivo the three 
dimensional orientation of molecular assemblies, microvascular 
trajectories and cellular arrangements by labelling them selectively with 
SWCNTs or MWCNTs. 
In this context, research on the molecular determinants of nanotube 
anisotropy acquires a fundamental relevance. Our results obtained by 
SQUID, become particularly enlightening to account for the magnetic 
anisotropy properties observed in water T2 by MRI. SQUID 
measurements reveal that the magnetic susceptibility anisotropy 
increases with shortening of the nanotubular structures and is not due to 
the contaminant Ni nanogranules. This indicates that the nanotubes 
themselves, and their association with the Ni nanogranules, constitute 
the main determinants of magnetic anisotropy in these preparations. 
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Moreover, the larger magnetic susceptibilities in the parallel than in the 
perpendicular directions detected by SQUID provide the physical basis to 
interpret the longer water T2 in the parallel than in perpendicular 
orientations detected by MRI. In MRI, longitudinal (T1) and transversal 
(T2) relaxation times are known to increase with the effective magnetic 
field  [22]. The resulting effective magnetic field on the sample 
depends then on the static magnetic field provided by the magnet (a 
constant value) and on the local magnetic field  originated by the 
SWCNTs or MWCNTs ( ). Thus the local magnetic 
field depends directly on the magnetic susceptibility of the nanotubes 
( ). Since  in SWCNTs preparations,
locallocal BB

||
 and consequently, the water T2 values 
observed by MRI are higher in the parallel than in the perpendicular 
orientation. 
The advance in generating a water soluble nanotube preparation merits 
also further comments. Previous preparations of pristine SWCNTs or 
MWCNts were highly water-insoluble and useless in medicinal chemistry 
applications and contrast agent development [115-122]. We have shown 
here that MWCNTs can be adequately solubilized in water, after size 
reduction by sonication and aminopyrene -  binding. The preparations 
obtained remain soluble and stable for several months, allowing for the 
development of therapeutic derivatives, imaging probes or both. 
Furthermore, we also show that the nanotube preparations are non-
toxic, as revealed by the MTT and LDH release tests, in contrast with 
previous reports that showed toxicity in nanotubes preparations 
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solubilized by detergents. Our results indicate that the nanotubular 
structures are non-toxic by themselves, at the concentration range 
required for MRI or therapeutic interventions and that previous toxicity 
results may have derived from the detergent used, rather than from the 
nanotubes [147].  
In summary, we investigated the determinants of magnetic anisotropy in 
carbon nanotube preparations and showed that the anisotropic behavior 
depends on the length and diameter of the nanotubular structures and 
may involve additional contributions from Ni nanoparticles fixed or 
adsorbed over the nanotube surface. Our results indicate, however, that 
the relative content of paramagnetic metals or superparamagnetic 
nanoparticles, decreases significantly with the oxidation time, suggesting 
a concomitant reduction in the proportion of bound metals to SWCNTs 
structures. Thus, the maximal anisotropy is observed in preparations 
containing the largest proportion of SWCNTs and the smallest content of 
paramagnetic metals and superparamagnetic nanoparticles. Together, 
present results suggest that the magnetic anisotropy of SWCNTs 
suspensions is dominated by the length and diameter of the carbon 
nanotubular structures, rather than by the contribution of free Ni or Ni 
nanoparticles, with a non-negligible contribution of Ni+ or Ni 
nanoparticles bound to or interacting with, the nanotubular structures. 
We believe these results open new avenues for the use of carbon 
nanotubes as directional contrast agents in MRI, as advanced probes to 
determine the three dimensional orientation of molecular assemblies in 
vivo and potentially to combine over the same nanoplatform, imaging 
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agents and therapeutic molecules. A patent covering these aspects has 
been filed [148]. 
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Conclusions 
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1. I reviewed the contrast agents currently available for multimodal 
imaging applications, their advantages and limitations. This 
review disclosed that the use of innovative strategies provided 
by Nanotechnology could improve the physicochemical and 
pharmacological properties of these molecules. On these 
grounds, I pursued the development of a novel 
superparamagnetic nanoparticle, its formulation as 
magnetoliposome and the implementation of carbon nanotubes 
as anisotropic contrast agents for MRI. 
2. I developed and characterized Nanotex, a novel 
superparamagnetic nanoparticle containing an Fe3O4 core, with 
polyacrylic acid coating. Nanotex, has shown comparable 
magnetic relaxivity properties, improved pharmacokinetics, 
reduced vascular retention and tissue accumulation and 
excellent results when used in “bolus tracking” experiments of 
perfusion imaging with MRI.  Taken together, these results 
support further development of the particle, as a contrast agent 
for Magnetic Resonance Imaging. 
3. I implemented a new anti-inflammatory nanoformulation based 
in magnetoliposomes containing Nanotex and ω-3 PUFA-EE, with 
advantageous properties as a theragnostic contrast agent. The 
particle may be combined with a fluorescent probe to yield a 
multimodal theragnostic agent detectable in vivo by MRI, 
fluorescence or both. This preparation demonstrated 
considerable antiinflamatory properties in a model of colonic 
inflammation and a previously unpredicted, outstanding 
antitumoral activity in a glioma model. 
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4. I investigated the magnetic properties of Carbon Nanotubes, 
both Single Walled and Multi Walled. I characterized the 
magnetic anisotropy observed in Single Walled Carbon 
Nanotubes as derived from the nanotubular grapheme structure 
and its interaction with contaminant paramagnetic 
nanoparticles. Magnetooptical techniques demonstrate also 
magnetic anisotropy of Multi Walled Carbon Nanotubes, even at 
room temperature. Magnetic Resonance Imaging confirms T2 
relaxation anisotropy for both types of Carbon Nanotubes at 
room temperature. 
5. In summary, I investigated, developed and proposed novel 
generations of nanotechnological contrast agents suitable for 
further development in the multimodal imaging market. 
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